

博士論文

Epidemiological surveillance and virological analyses of highly
pathogenic H5N1 avian influenza viruses in Indonesia.

(インドネシアにおける高病原性 H5N1 鳥インフルエンザウイルスの
疫学的調査及びウイルス学的解析)

今村剛朗

Epidemiological surveillance and virological analyses of highly pathogenic H5N1 avian influenza viruses in Indonesia.

(インドネシアにおける高病原性 H5N1 鳥インフルエンザウイルスの疫学的調査及びウイルス学的解析)

病因病理学専攻 ウイルス感染分野

指導教員：河岡義裕

申請者：今村剛朗

共同研究者：山田晋弥、岩附(堀本)研子、Chairul A. Nidom

ABSTRACT	3
PREFACE	5
MATERIALS AND METHODS	11
CHAPTER 1: Epidemiological surveillance and characterization of highly pathogenic H5N1 avian influenza viruses in Indonesia isolated between 2010 and 2016	
INTRODUCTION	20
RESULTS	24
DISCUSSION	57
CHAPTER 2: Amino acid substitutions in the PB2 protein of an H5N1 avian influenza virus enhance its replication efficiency and pathogenicity in mammalian hosts.	
INTRODUCTION	63
RESULTS	68
DISCUSSION	103
CONCLUSION	109
ACKNOWLEDGEMENTS	110
REFERENCES	112

1 **Abstract**

2 Highly pathogenic avian influenza (HPAI) H5N1 viruses have been circulating in
3 Indonesia since 2003, and sporadic human H5N1 cases were reported until 2017. However,
4 there are no reports on the epidemiology or virological characteristics of the currently
5 circulating HPAI H5N1 viruses, and their potential to cause a human endemic or pandemic is
6 unknown. With the aim of elucidating the characteristics of the currently circulating HPAI
7 H5N1 viruses in Indonesia, I conducted epidemiological surveillance of poultry and swine in
8 Indonesia between 2010 and 2016. Two distinct sub-clades of H5N1 viruses, clade 2.1.3 and
9 clade 2.3.2.1d, were identified, and the clade 2.3.2.1d strains appear to have recently become
10 dominant among poultry. Clade 2.3.2.1d strains showed mammalian-adaptive traits including
11 high viral polymerase activity and moderate replication capability in human lung epithelial
12 cells, and high virulence in BALB/c mice. My findings indicate that further, continuous
13 surveillance of HPAI H5N1 viruses in Indonesia is warranted in order to detect the emergence
14 of viruses with endemic or pandemic capability.

15 Among the Indonesian HPAI H5N1 viruses analyzed, I identified two genetically
16 closely related viruses with different replication efficiency and pathogenicity in mammalian
17 hosts. Further analysis of these two viruses revealed two amino acid mutations in the viral

18 PB2 protein (PB2-109A and PB2-758T) that enhanced viral replication efficiency in human
19 lung epithelial cells and pathogenicity in BALB/c mice. The mechanism by which these two
20 PB2 mutations enhance virulence in mammalian hosts has not yet been elucidated, but my
21 findings are valuable for assessing the risk of avian-to-human transmission of highly
22 pathogenic H5N1 avian influenza field isolates.

23

24

25

26

27

28

29

30

31

32

33

34

35 **Preface**

36 Influenza viruses are members of the family *Orthomyxoviridae*, which have a
37 negative-sense, single-stranded, segmented RNA genome [1, 2]. There are four genera of
38 influenza viruses: A, B, C, and D. Human influenza A and B viruses cause annual seasonal
39 epidemics. Wild aquatic birds are natural reservoirs of influenza A viruses, which are
40 zoonotic pathogens infecting humans as well as various other animal species. The natural
41 reservoirs of influenza B viruses are unknown. Influenza B viruses circulate mainly among
42 humans, but there have been several reports of infection in seals [3, 4]. Influenza C viruses
43 cause mild respiratory illness among humans, especially children [5-7]. Influenza D viruses
44 primarily affect cattle and their zoonotic potential has not yet been clarified [8, 9].

45 Influenza A virus is composed of eight segments of single-stranded, negative-sense
46 RNA that each encodes one or more viral proteins (Fig. 1) [1, 10, 11]. Replication and
47 transcription of viral RNA require three polymerase proteins [polymerase basic protein 2
48 (PB2), polymerase basic protein 1 (PB1) and polymerase acidic protein (PA)] , which are
49 encoded by the three largest segments. The seventh and eighth segments each encode two
50 viral proteins that are essential to the nuclear export of newly synthesized viral
51 ribonucleoprotein (vRNP) complexes, virion assembly, or interactions with the host immune

52 response. The surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) are
53 encoded by the fourth and the sixth segment, respectively. HA is critical to viral binding and
54 internalization to the host cell, whereas NA promotes the release of viruses from the cell
55 surface (Fig. 2).

56

57

58

59

60

61

62

63


64

65

66

67


68



69

70 **Figure 1. The structure of influenza virus**

71 Influenza A virus is composed of eight segments of single-stranded, negative-sense RNA
 72 within a viral envelope. The viral envelope is coated with matrix protein (M1), and embedded
 73 with surface glycoproteins HA and NA, and M2 ion-channel protein. The viral RNA
 74 segments are associated with nucleoprotein (NP) and three polymerase proteins (PB2, PB1,
 75 and PA). The figure was cited from [11].



76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93

Figure 2. Influenza virus life cycle

Influenza A virus binds to the cell surface and enters the cell via HA-mediated endocytosis. Then, the viral nucleoprotein (vRNP) is uncoated in the cytoplasm, and subsequently imported into the nucleus, where replication and transcription occur. After messenger RNA (mRNA) exportation and translation in the cytoplasm, newly synthesized viral proteins are transported back to the nucleus and formed into vRNP. The assembly and budding of progeny virions occur at the plasma membrane. The figure was adapted from [12].

94 On the basis of the antigenicity of the two surface glycoproteins, HA and NA,
95 influenza A viruses are classified into 18 HA subtypes (H1–H18) and 11 NA subtypes (N1–
96 N11). Wild aquatic birds are natural reservoir for most subtypes of influenza A viruses,
97 except for subtype H17N10 and H18N11 which are only found in bats [1, 2, 13, 14]. Among
98 humans, influenza A viruses of the H1N1, H1N2, H2N2, H3N2, and H3N8 subtypes have
99 established circulation at least once [2].

100 Influenza A viruses evolve via accumulation of mutations and rearrangements of
101 their viral RNA segments, which is termed reassortment [2]. These processes lead to the
102 introduction of new influenza A viruses into human populations, causing global epidemics,
103 called pandemics. Among the four recorded influenza pandemics, H1N1 Spanish influenza in
104 1918–1919, H2N2 Asian influenza in 1957, and H3N2 Hong Kong influenza in 1968 involve
105 avian influenza viruses [2, 12]. The H1N1 pandemic in 2009 originated from reassortment of
106 swine, avian, and human influenza A viruses [12].

107 Most subtypes of influenza A viruses are maintained asymptotically in the
108 Orders *Anseriformes* (i.e., ducks, geese, and swans) and *Charadriiformes* (i.e., gulls, terns,
109 surfbirds, and sandpipers) [15]. However, there exist highly pathogenic avian influenza
110 (HPAI) viruses that cause significant mortality in chickens [16]. All HPAI viruses known to

111 date belong to either the H5 or H7 subtype. One characteristic feature of the HA of HPAI
112 viruses is the presence of polybasic amino acids at the HA cleavage site. Low pathogenic
113 avian influenza (LPAI) viruses possess a single arginine residue at the cleavage site, which
114 can be cleaved in limited organs, resulting in localized infection in the respiratory or intestinal
115 tract in poultry. In contrast, the polybasic cleavage site can be cleaved by ubiquitous
116 proteases, broadening viral tissue tropism and resulting in systemic infections and enhanced
117 virulence in poultry [2, 11, 17, 18].

118 In 1996, an HPAI virus of the H5N1 subtype was isolated from a farmed goose in
119 Guangdong province, China [19]. In 1997, an outbreak of H5N1 viruses among poultry and
120 18 cases of human infection were reported in Hong Kong [2, 20, 21]. Since then, HPAI H5N1
121 viruses have caused numerous outbreaks in poultry worldwide, especially in China, Southeast
122 Asia, and Africa [22]. Transmission of HPAI H5N1 viruses to humans has been monitored by
123 the WHO, and a total of 860 human infection cases, including 454 lethal cases, have been
124 reported as of September, 2018 [23, 24]. Thus, aside from their damage to the poultry
125 industry, HPAI H5N1 viruses pose an imminent threat to humans due to their potential to
126 cause epidemics and pandemics.

127

128 **Materials and Methods**

129 **Ethics and biosafety**

130 All experiments with H5N1 viruses were performed in biosafety level 3 (BSL3)
131 laboratories at the University of Tokyo, which were approved for such use by the Ministry of
132 Agriculture, Forestry, and Fisheries, Japan. All experiments with mice were performed in
133 accordance with the University of Tokyo's Regulations for Animal Care and Use and were
134 approved by the Animal Experiment Committee of the Institute of Medical Science, the
135 University of Tokyo (P15-10).

136

137 **Cells**

138 Madin-Darby canine kidney (MDCK) cells were cultured in minimal essential
139 medium (MEM) containing 5% newborn calf serum (NCS), vitamins, essential amino acids,
140 and antibiotics. MDCK cells expressing the PB2 protein of A/Puerto Rico/8/34 (H1N1, PR8)
141 were cultured in the same medium as MDCK cells with blasticidin supplementation. A549
142 human lung adenocarcinoma epithelial cells were cultured in Ham's F-12K (Kaighn's)
143 medium containing 10% fetal bovine serum (FBS) and antibiotics. Human embryonic kidney
144 293T cells and DF-1 chicken-embryo fibroblast cells were grown in Dulbecco's modified

145 Eagle medium (DMEM) containing 10% FBS and antibiotics. MDCK, A549, and 293T cells
146 were incubated at 37°C with 5% CO₂. DF-1 cells were incubated at 39°C, with 5% CO₂.
147 Normal human bronchial epithelial (NHBE) cells (Lonza, Walkersville, MD) were cultured
148 and differentiated in an air-liquid interface system [25, 26]. Briefly, the apical surface of the
149 cells was exposed to a humidified 95% air/5% CO₂ environment, and the basolateral medium
150 was changed every two days.

151

152 **Sample collection and virus isolation**

153 Tracheal, cloacal, nasal, or fecal swab samples were collected from poultry and
154 swine in various locations in Indonesia from 2010 through 2016 (Table 2). The collected
155 samples were inoculated into 10-day-old embryonated eggs, and the allantoic fluid was tested
156 for hemagglutination using chicken red blood cells. Hemagglutination-positive allantoic fluid
157 underwent reverse transcription PCR (RT-PCR) and direct sequencing. Sequence-confirmed
158 H5N1 samples were stored at -80°C.

159

160

161

162 **Isolation of viral RNA, RT-PCR, and generation of viruses by reverse genetics**

163 Viral RNA was extracted from allantoic fluid of embryonated chicken eggs by
164 using the QIAamp viral RNA minikit (Qiagen, Hilden, Germany). Extracted RNA was
165 reverse-transcribed with Superscript III (Invitrogen, Carlsbad, CA) and universal primers
166 specific for influenza A virus genes to generate cDNA. The resulting products were PCR-
167 amplified by using Phusion High-Fidelity DNA polymerase (New England BioLabs, Ipswich,
168 MA) with specific primers for each virus gene and cloned into the viral expression plasmid
169 pHH21 [27]. Mutations in the PB2 and NA genes were generated by PCR amplification of the
170 respective construct with primers possessing the desired mutations. Primer sequences are
171 listed in Table 1. All constructs were sequenced to ensure the absence of unwanted mutations.
172 All avian, reassortant, and mutant viruses were generated in 293T cells by use of plasmid-
173 based reverse genetics, as described previously[27]. The supernatant of transfected 293T cells
174 was collected after an incubation time of less than 24 hours in order to avoid the emergence of
175 mammalian-adaptive mutations, and the supernatant was inoculated into nine- or ten-day-old
176 embryonated chicken eggs. After an incubation of up to 48 hours, the allantoic fluid of the
177 inoculated eggs was harvested and stored at -80°C. The virus titers were determined by using
178 plaque assays in MDCK, A549, and DF-1 cells, respectively.

179 **Table 1. List of primers**

Primer	Sequence	Description
A-u12g	5'-AGCGAAAGCAGG-3'	RT-PCR
uniPB2-1	5'-AGCGAAAGCAGGTC-3'	RT-PCR
uniPB2-2341R	5'-AGTAGAAACAAGGTCGTTT-3'	RT-PCR
uniPB1-1	5'-AGCGAAAGCAGGCA-3'	RT-PCR
uniPB1-2341R	5'-AGTAGAAACAAGGCATT-3'	RT-PCR
uniPA-1	5'-AGCGAAAGCAGGTAC-3'	RT-PCR
uniPA-2233R	5'-AGTAGAAACAAGGTACTT-3'	RT-PCR
uniHA-1	5'-AGCAAAAAGCAGGGG-3'	RT-PCR
H5-u12+20F	5'-AGCAAAAAGCAGGGTTCAATCTGTCAAAATGG-3'	RT-PCR
H5-u13+20R	5'-AGTAGAAACAAGGGTGTTTTAACTACAATCTG-3'	RT-PCR
uniNP-1	5'-AGCGAAAGCAGGGTA-3'	RT-PCR
uniNP-1565R	5'-AGTAGAAACAAGGGTATTTTT-3'	RT-PCR
uniNA-1	5'-AGCGAAAGCAGGAGT-3'	RT-PCR
uniNA-1413R	5'-AGTAGAAACAAGGAGTTTTT-3'	RT-PCR
uniM-1	5'-AGCGAAAGCAGGTAG-3'	RT-PCR
uniM-1027R	5'-AGTAGAAACAAGGTAGTTTTT-3'	RT-PCR
WSNM-1F	5'-AGCAAAAAGCAGGTAGATATTGAAAGATGAG-3'	RT-PCR
WSNM-1027R	5'-AGTAGAAACAAGGTAGTTTTTACTCCAGC-3'	RT-PCR
uniNS-1	5'-AGCGAAAGCAGGGTG-3'	RT-PCR
uniNS-890R	5'-AGTAGAAACAAGGGTGTTTT-3'	RT-PCR
Bm-HA-1	5'-TATTCGTCTCAGGGAGCAAAGCAGGGG-3'	pHH21 cloning
Bm-HA-u12+9F	5'-TATTCGTCTCAGGGAGCAAAGCAGGGGTTCAATCTG-3'	pHH21 cloning
Bm-HA-u13+5R	5'-ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTTAACT-3'	pHH21 cloning
Bm-NA-1	5'-TATTCGTCTCAGGGAGCAAAGCAGGAGT-3'	pHH21 cloning
Bm-NA-u12+2F	5'-TATTCGTCTCAGGGAGCAAAGCAGGAGTTC-3'	pHH21 cloning
Bm-NA-1413R	5'-ATATCGTCTCGTATTAGTAGAAACAAGGAGTTTTT-3'	pHH21 cloning
Bm-NA-u13+5R	5'-ATATCGTCTCGTATTAGTAGAAACAAGGAGTTTTTGAACA-3'	pHH21 cloning
Bm-PB2-1	5'-TATTCGTCTCAGGGAGCAAAGCAGGTC-3'	pHH21 cloning
Bm-PB2-u12+9F	5'-TATTCGTCTCAGGGAGCAAAGCAGGTCAATATATT-3'	pHH21 cloning
Bm-PB2-2341R	5'-ATATCGTCTCGTATTAGTAGAAACAAGGTCGTTT-3'	pHH21 cloning
Bm-PB2-u13+6R	5'-ATATCGTCTCGTATTAGTAGAAACAAGGTCGTTTTTAAAC-3'	pHH21 cloning
Bm-PB1-1	5'-TATTCGTCTCAGGGAGCAAAGCAGGTA-3'	pHH21 cloning
Bm-PB1-2341R	5'-ATATCGTCTCGTATTAGTAGAAACAAGGCATT-3'	pHH21 cloning
Bm-PA-1	5'-TATTCGTCTCAGGGAGCAAAGCAGGTAC-3'	pHH21 cloning
Bm-PA-2233R	5'-ATATCGTCTCGTATTAGTAGAAACAAGGTACTT-3'	pHH21 cloning
Ba-NP-1	5'-TATTCGTCTCAGGGAGCAAAGCAGGGTA-3'	pHH21 cloning
Ba-NP-u12+15F	5'-TATTCGTCTCAGGGAGCAAAGCAGGGTAGATAATCACTCACC-3'	pHH21 cloning
Ba-NP-1565R	5'-ATATGGTCTCGTATTAGTAGAAACAAGGGTATTTTT-3'	pHH21 cloning
Ba-NP-u13+1R	5'-ATATGGTCTCGTATTAGTAGAAACAAGGGTATTTTT-3'	pHH21 cloning
Bm-M-1	5'-TATTCGTCTCAGGGAGCAAAGCAGGTAG-3'	pHH21 cloning
Bm-M-u12+2F	5'-TATTCGTCTCAGGGAGCAAAGCAGGTAGAT-3'	pHH21 cloning
Bm-M-1027R	5'-ATATCGTCTCGTATTAGTAGAAACAAGGTAGTTTTT-3'	pHH21 cloning
Bm-M-u13+2R	5'-ATATCGTCTCGTATTAGTAGAAACAAGGTAGTTTTTAC-3'	pHH21 cloning
Bm-NS-1	5'-TATTCGTCTCAGGGAGCAAAGCAGGGTG-3'	pHH21 cloning
Bm-NS-890R	5'-ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT-3'	pHH21 cloning
PB2-Clal-F-1	5'-ACAATCGATGCCGCCACCATTGGAGAGAATAAAAAGAA-3'	pCAGGS cloning
PB2-Clal-F-2	5'-ACAATCGATGCCGCCACCATTGGAAGAAATAAAAAGAA-3'	pCAGGS cloning
PB2-Clal-F-4	5'-ACAATCGATGCCGCCACCATTGGAGAGAATAAAAAGAA-3'	pCAGGS cloning
PB2-Sph-F-1	5'-ACAGCATGCCGCCACCATTGGAGAGAATAAAAAGAA-3'	pCAGGS cloning
PB2-NheI-R-1	5'-ACAGCTAGCCTAATTTGATGGCCATCCGAATT-3'	pCAGGS cloning
PB2-NheI-R-3	5'-ACAGCTAGCCTAATTTGGTGCCATCCGAATCTTTTGGTCGC-3'	pCAGGS cloning
PB2-NheI-R-4	5'-ACAGCTAGCCTAATTTGGTGCCATCCGAATT-3'	pCAGGS cloning
PB1-Clal-F-1	5'-ACAATCGATGCCGCCACCATTGGATGTCAATCCGACT-3'	pCAGGS cloning
PB1-Clal-F-8	5'-ACAATCGATGCCGCCACCATTGGATGTCAATCCGACT-3'	pCAGGS cloning
PB1-Clal-F-9	5'-ACAATCGATGCCGCCACCATTGGATGTCAATCCGACT-3'	pCAGGS cloning
PB1-NheI-R-1	5'-ACAGCTAGCCTAATTTGCCGTCTGAGCTCTT-3'	pCAGGS cloning
PB1-NheI-R-5	5'-ACAGCTAGCCTAATTTGCCGT-3'	pCAGGS cloning
PB1-NheI-R-7	5'-ACAGCTAGCCTAATTTGCCG-3'	pCAGGS cloning
PA-Clal-F-1	5'-ACAATCGATGCCGCCACCATTGGAAGATTTTGTGCGACA-3'	pCAGGS cloning
PA-Clal-F-2	5'-ACAATCGATGCCGCCACCATTGGAAGACTTTGTGCGACAAT-3'	pCAGGS cloning
PA-Clal-F-4	5'-ACAATCGATGCCGCCACCATTGGAAGATTTTGTGCG-3'	pCAGGS cloning
PA-Clal-F-5	5'-ACAATCGATGCCGCCACCATTGGAAGACTTTGTGCG-3'	pCAGGS cloning
PA-SphI-F-1	5'-ACAGCATGCCGCCACCATTGGAAGATTTTGTGCG-3'	pCAGGS cloning
PA-NheI-R-1	5'-ACAGCTAGCCTATTTTCAAGTGCATGTGCGAGGAA-3'	pCAGGS cloning
PA-NheI-R-2	5'-ACAGCTAGCCTATTTTCAAGTGCATGTGCGAGGAA-3'	pCAGGS cloning
PA-NheI-R-5	5'-ACAGCTAGCCTATTTTCAAGTGCATGTGCGAGGAA-3'	pCAGGS cloning
PA-NheI-R-6	5'-ACAGCTAGCCTATTTTCAAGTGCATGTGCGAGGAA-3'	pCAGGS cloning

180

181

182 **Table 1. List of primers (continued)**

Primer	Sequence	Description
PA-Sphi-R-1	5'-ACAGCATGCCTATTTCAAGTCA-3'	pCAGGS cloning
PA-XhoI-R-1	5'-ACACTCGAGCTATTTCAAGTCA-3'	pCAGGS cloning
NP-ClaI-F-1	5'-ACAATCGATGCCGCCACCATGGCGTCTCAAGGCACCAA-3'	pCAGGS cloning
NP-ClaI-F-2	5'-ACAATCGATGCCGCCACCATGGCGTCTCAAGGCACC-3'	pCAGGS cloning
NP-NheI-R-1	5'-ACAGCTAGCTTAATTGTCATACCTCTGCATT-3'	pCAGGS cloning
NP-NheI-R-2	5'-ACAGCTAGCTTAATTGTCATACCTCTGCATTGTC-3'	pCAGGS cloning
NP-NheI-R-3	5'-ACAGCTAGCTTAATTGTCATACCTCTGCATTGTC-3'	pCAGGS cloning
UT521-UT541-HA-LPAI-F	5'-CTCAGAAATAGCCCTCAAAGAGAGAGAGGACTATTTGGAGC-3'	HA mutagenesis pHH21
UT521-UT541-HA-LPAI-R	5'-CCAAATAGTCTCTCGTTTCTTTGAGGGCTATTTCTGAGCCC-3'	HA mutagenesis pHH21
UT14-HA-LPAI-F	5'-CACACACGCTCTGTGCTATTTGGAGCTATAGCAGG-3'	HA mutagenesis pHH21
UT14-HA-LPAI-R	5'-CACACACGCTCTGGACTGTTGGAGCTATAGCAGG-3'	HA mutagenesis pHH21
UT17-HA-LPAI-F	5'-CACACACGCTCTGTCTCTAGTCTCTTTGAGGGCTATTTCTGAGCCCTGTCGC-3'	HA mutagenesis pHH21
UT17-HA-LPAI-R	5'-CACACACGCTCTGTCTCTAGTCTCTTTGAGGACTATTTCTGAGCCCAGTGC-3'	HA mutagenesis pHH21
UT64-HA-LPAI-F	5'-CTCAGAAATAGTCTCAAAGAGAGACAAGAGGACTGTTGGAGC-3'	HA mutagenesis pHH21
UT64-HA-LPAI-R	5'-CAAACAGTCTCTGTCTCTTTGAGGACTATTTCTGAGCCCA-3'	HA mutagenesis pHH21
UT167-UT173-HA-LPAI-F	5'-AATAGTCTCAAAGAGAGAGACAAGAGGACTGTTGGGGCTA-3'	HA mutagenesis pHH21
UT167-UT173-HA-LPAI-R	5'-CAAACAGTCTCTGTCTCTTTGAGGACTATTTCTGAGCCCA-3'	HA mutagenesis pHH21
NA-521-I32L-F	5'-GTTACAAATGGGAACATAATCTCTTATGGGTCAGTCAT-3'	NA mutagenesis pHH21
NA-521-I32L-R	5'-CCCTTTCTGAATTGAATGACTGACCCATAAGGAGATTATGT-3'	NA mutagenesis pHH21
NA-521-N50S-F	5'-TCAACACCAAGCTGAATCAATCAACAATAAACCCTTTAC-3'	NA mutagenesis pHH21
NA-521-N50S-R	5'-CTCAGTAAGAGGTTAGTATTGCTGATTGATTAGCTTGGTGT-3'	NA mutagenesis pHH21
NA-521-K53N-F	5'-TCAACACCAAGCTGAATCAATCAACAATAAACCCTTTAC-3'	NA mutagenesis pHH21
NA-521-K53N-R	5'-CTCAGTAAGAGGTTAGTATTGCTGATTGATTAGCTTGGTGT-3'	NA mutagenesis pHH21
NA-521-T1111-F	5'-TCATGCTCCCACTTGAATGACAGAACTTTCTTAACTCAGGG-3'	NA mutagenesis pHH21
NA-521-T1111-R	5'-AAGGCTCCCTGAGTTAAGAAGAAATCTGCATTCCAAGTGGG-3'	NA mutagenesis pHH21
NA-521-L120M-F	5'-TCAGGGAGCCTTGATGAATGACAAGCACTCAACGGAAGTGC-3'	NA mutagenesis pHH21
NA-521-L120M-R	5'-TTTGACAGTTCCGTTGGAGTGTGTGTCATTCATCAAGGC-3'	NA mutagenesis pHH21
NA-521-M143V-F	5'-GAACATTAATGAGTTGCTCTGTGGGTGA-3'	NA mutagenesis pHH21
NA-521-M143V-R	5'-AGCCTCACCCACAGGACAACCTATTAAT-3'	NA mutagenesis pHH21
NA-521-major01-F	5'-TCAATCAGCAATACTAACCCTTACTGAGAAAGCTGTGGCTTC-3'	NA mutagenesis pHH21
NA-521-major01-R	5'-CTCAGTAAGAGGTTAGTATTGCTGATTGATTAGCTTGGTGT-3'	NA mutagenesis pHH21
NA-541-L32I-F	5'-GTTACAAATGGGAACATAATCTCAATATGGGTGAGTCAT-3'	NA mutagenesis pHH21
NA-541-L32I-R	5'-CCCTTTCTGAATTGAATGACTGACCCATATTGAGATTATGT-3'	NA mutagenesis pHH21
NA-541-S50N-F	5'-TCAACACCAAGCTGAATCAATCAACAATAAACCCTTTAC-3'	NA mutagenesis pHH21
NA-541-S50N-R	5'-CTCAGTAAGAGGTTAGTATTGCTGATTGATTAGCTTGGTGT-3'	NA mutagenesis pHH21
NA-541-N53K-F	5'-TCAACACCAAGCTGAATCAATCAACAATAAACCCTTTAC-3'	NA mutagenesis pHH21
NA-541-N53K-R	5'-CTCAGTAAGAGGTTAGTATTGCTGATTGATTAGCTTGGTGT-3'	NA mutagenesis pHH21
NA-541-I111T-F	5'-TCATGCTCCCACTTGAATGACAGAACTTTCTTAACTCAGGG-3'	NA mutagenesis pHH21
NA-541-I111T-R	5'-AAGGCTCCCTGAGTTAAGAAGAAATCTGCATTCCAAGTGGG-3'	NA mutagenesis pHH21
NA-541-M120L-F	5'-TCAGGGAGCCTTGATGAATGACAAGCACTCAACGGAAGTGC-3'	NA mutagenesis pHH21
NA-541-M120L-R	5'-TTTGACAGTTCCGTTGGAGTGTGTGTCATTCAGCAAGGC-3'	NA mutagenesis pHH21
NA-541-V143M-F	5'-GAACATTAATGAGTTGCTCTATGGGTGA-3'	NA mutagenesis pHH21
NA-541-V143M-R	5'-AGCCTCACCCATAGGACAACCTATTAAT-3'	NA mutagenesis pHH21
NA-chimera1-R	5'-GGCTCTCAATAACAACACATCTCAATATGGGTGGAACCG-3'	NA mutagenesis pHH21
NA-chimera2-F	5'-AGGACAACAATATAAGGATCGGTTCC-3'	NA mutagenesis pHH21
PB2-521-A109V-02-F	5'-TAGGAATGGGCAACGACAAGTGCAGTCCATTATCCAAAGGTTT-3'	PB2 mutagenesis pHH21
PB2-521-A109V-02-R	5'-GTATGTTTTGTAACCTTTGGATAATGGACTGCAC-3'	PB2 mutagenesis pHH21
PB2-521-A292T-F	5'-AGCACACAATTTGGTGGGACAGAATGGTGGACATCCCTTA-3'	PB2 mutagenesis pHH21
PB2-521-A292T-R	5'-GCCTAAGGATGTCCACCATTTGTCACCACCAATTTGTGTG-3'	PB2 mutagenesis pHH21
PB2-521-K369N-F	5'-GAGGAATTCACAATGGTTGGGCGGAATGCAACAGCT-3'	PB2 mutagenesis pHH21
PB2-521-K369N-R	5'-TTGCTTTCCTCAGGATAGCTGTTGCATTCGCCCAA-3'	PB2 mutagenesis pHH21
PB2-521-L447Q-F	5'-CAAAAGTGCTATTTCAGAAGTGGGGAATTTGAACCCA-3'	PB2 mutagenesis pHH21
PB2-521-L447Q-R	5'-CAATCCCCAGTCTGAAATAGCACTTTGCGTCT-3'	PB2 mutagenesis pHH21
PB2-521-T758I-F	5'-ACAGCGACCAAAAGAATTCGGATGGCCATCAATAGTGTGC-3'	PB2 mutagenesis pHH21
PB2-521-T758I-R	5'-AATTCGACACTAATTTGATGGCCATCCGAATCTTTGGTGC-3'	PB2 mutagenesis pHH21
PB2-541-V109A-F	5'-AATGGGCCAACGACAAGTGCAGCCATTATCCAAAGTTTAC-3'	PB2 mutagenesis pHH21
PB2-541-V109A-02-R	5'-GTATGTTTTGTAACCTTTGGATAATGGGCTGCAC-3'	PB2 mutagenesis pHH21
PB2-541-T292A-F	5'-AGCACACAATTTGGTGGGCAAGAATGGTGGACATCCCTTA-3'	PB2 mutagenesis pHH21
PB2-541-T292A-R	5'-GCCTAAGGATGTCCACCATTTGTCACCACCAATTTGTGTG-3'	PB2 mutagenesis pHH21
PB2-541-N369K-F	5'-GAGGAATTCACAATGGTTGGGCGGAATGCAACAGCT-3'	PB2 mutagenesis pHH21
PB2-541-N369K-R	5'-TTGCTTTCCTCAGGATAGCTGTTGCCATTCGCCCAA-3'	PB2 mutagenesis pHH21
PB2-541-Q447L-F	5'-CAAAAGTGCTATTTCTGAACTGGGGAATTTGAACCCA-3'	PB2 mutagenesis pHH21
PB2-541-Q447L-R	5'-CAATCCCCAGTTCAGAAATAGCACTTTGCGTCT-3'	PB2 mutagenesis pHH21
PB2-541-I758T-F	5'-ACAGCGACCAAAAGAATTCGGATGGCCATCAATAGTGTGC-3'	PB2 mutagenesis pHH21
PB2-541-I758T-R	5'-AATTCGACACTAATTTGATGGCCATCCGAATCTTTGGTGC-3'	PB2 mutagenesis pHH21
PB2-chimera1-R	5'-CTTCTCTTCTTCTGTCAGCG-3'	PB2 mutagenesis pHH21
PB2-chimera2-F	5'-CAAAAGAACAAGTGGATCATCCGTC-3'	PB2 mutagenesis pHH21

183

184 Primers used for RT-PCR, pHH21 cloning, pCAGGS cloning, and introduction of amino acid
 185 mutations are listed above.

186 **Viral replication assay**

187 Triplicate wells of confluent A549 cells or DF-1 cells were infected with viruses at
188 a multiplicity of infection (MOI) of 0.0002, and incubated for 1 hour. The infected virus loads
189 were calculated by using virus titers measured in the respective A549 cells and DF-1 cells.
190 The incubation temperature was set to 33°C or 37°C for A549 cells (temperatures of the
191 human lower and upper respiratory tract), and to 39°C for DF-1 cells (body temperature of
192 birds). After the 1-hour-incubation, A549 cells were further incubated in F-12K containing
193 0.3% bovine serum albumin (BSA) at 33°C or 37°C. DF-1 cells were further incubated in
194 DMEM containing 0.3% BSA at 39°C. Supernatant was harvested at 24-hour-intervals, and
195 frozen at -80°C. Virus titers in the collected supernatant at each time point were determined
196 by use of plaque assays in MDCK cells; 6- (1-tosylamido-2-phenyl) ethyl chloromethyl
197 ketone (TPCK)-treated trypsin was added for replication efficiency analysis and plaque assays
198 of reassortant virus strains possessing the HA segment of PR8 or a monobasic cleavage site.

199

200 **Mouse experiments**

201 Six-week-old, female, specific-pathogen-free (SPF) BALB/c mice (SLC, Japan)
202 were used for mouse experiments. To analyze the pathogenicity of H5N1 viruses isolated

203 during surveillance activities, four to five mice/group were anesthetized with isoflurane and
204 intranasally inoculated with 1×10^3 plaque-forming units (PFU) of virus in a $50\text{-}\mu\text{l}$ volume,
205 using virus titers measured in MDCK cells. The mice were monitored daily for clinical signs
206 of infection and changes in body weight and mortality for 12 days. To determine the dose
207 lethal to 50% of mice (MLD_{50}), four or five mice/group were intranasally inoculated with 10^1
208 to 10^6 PFU of virus in a $50\text{-}\mu\text{l}$ volume. The mice were monitored and checked for changes in
209 body weight and mortality for 14 days post-infection. MLD_{50} values were calculated by using
210 the method of Reed & Muench [28]. For virus replication in mouse organs, groups of mice
211 (six mice/group) were intranasally infected with 1×10^3 PFU of virus in a $50\text{-}\mu\text{l}$ volume. Three
212 mice in each group were euthanized on days three and six post-infection, respectively. Organs
213 (brain, liver, kidney, spleen, colon, heart, trachea, lungs, and nasal turbinate) were collected,
214 and their virus titers were measured by use of plaque assays in MDCK cells.

215

216 **Mini-replicon assay**

217 A549 cells and DF-1 cells were transfected with $0.1\ \mu\text{g}$ each of the pCAGGS
218 constructs encoding the polymerase proteins PB1, PA, nucleoprotein (NP) and wild-type or
219 mutant PB2, together with $0.1\ \mu\text{g}$ each of the pHH21 constructs encoding firefly luciferase

220 and Renilla luciferase as an internal control [29, 30]. The transfected A549 cells were
221 incubated either at 33°C for 48 hours, or at 37°C for 24 hours, respectively. The transfected
222 DF-1 cells were incubated at 39°C for 24 hours. After incubation, the cells were lysed and the
223 luciferase activity was determined by using the dual-luciferase system detector kit (Promega,
224 Madison, WI). The luciferase activity values were normalized to the Renilla activity.

225

226 **HA receptor binding assay**

227 Virus binding to sialic acid receptors was analyzed using a solid-phase binding
228 assay with the Octet RED instrument from ForteBio (Menlo Park, CA, USA), as previously
229 described [31, 32]. The receptor analogs used were *N*-acetylneuraminic acid linked to
230 galactose by either an α 2,3-linkage (Neu5Ac(α 2-3)LacNAc-PGA-Biotin) or an α 2,6-
231 linkage (Neu5Ac(α 2-6)LacNAc-PGA-Biotin) (Tokyo Chemical Industry, Tokyo, Japan),
232 and they were loaded onto streptavidin biosensors. Replication-incompetent PB2-knockout
233 virus strains possessing the PR8 strain backbone with the HA and NA segments of the target
234 virus strains were generated by using reverse genetics. The HA cleavage site of the target
235 HPAI H5N1 virus strains was transformed from polybasic into monobasic so that the receptor
236 binding assay could be conducted in the BSL2 facility. The generated virus strains were

237 propagated in MDCK cells expressing the PB2 protein of PR8. Generated viruses were
238 concentrated by ultracentrifugation at 28000 rotations per minute (rpm) for 2 hours using a
239 25% sucrose cushion, and 5 μ g of concentrated virus was used for each receptor binding
240 assay. A/Vietnam/1203/2004 (H5N1) bound to Sia α 2,3Gal (pink), and
241 A/Kawasaki/173/2001 (H1N1) bound to Sia α 2,6Gal served as controls. An analyzed virus
242 strain that was not loaded with glycoprotein served as a baseline.

243

244 **Immunofluorescence assay**

245 After viral infection or plasmid transfection, A549 cells were fixed with 4%
246 paraformaldehyde and then permeabilized with 0.2% Triton X-100 [33]. After blocking,
247 antigens were probed with mouse anti-WSN NP 3/1 monoclonal antibody, mouse anti-Aichi
248 NP 2S 347/4 monoclonal antibody, or mouse anti-PB2-18/1 monoclonal antibody, followed
249 by Alexa Fluor 488 anti-mouse IgG (Life Technologies, Carlsbad, CA, United States). Nuclei
250 were stained with Hoechst 33342 (Life Technologies, Carlsbad, CA, United States). The cells
251 were then imaged by using a laser-scanning microscope (LSM780 system, Carl Zeiss) and
252 analyzed with Zen software (Carl Zeiss).

253

254 **Chapter 1: Epidemiological surveillance and characterization of highly pathogenic**


255 **H5N1 avian influenza viruses isolated in Indonesia between 2010 and 2016**

256

257 **Introduction**

258 HPAI H5N1 viruses have been circulating in poultry in Indonesia since 2003 [34-
259 36]. Poultry production in Indonesia is diverse, ranging from backyard poultry farms to large
260 industrial integrated poultry farms. Uncontrolled movement of live poultry and poor
261 biosecurity practices, including trades in live bird markets, continue to be a problem, and the
262 surveillance system for HPAI is still not well organized [37]. Despite the Indonesian
263 government's attempt to eradicate H5N1 viruses through culling of infected chickens and
264 poultry vaccination, HPAI H5N1 viruses are still widely circulating in Indonesia [34, 35, 38,
265 39]. Along with the enzootic state among poultry, 200 human H5N1 cases in Indonesia,
266 including 168 lethal cases, have been reported to the WHO as of September, 2018 (Fig. 3)
267 [23]. The latest human H5N1 case in Indonesia was reported in September, 2017, which
268 resulted in a fatal outcome [40]. HPAI H5N1 viruses in Indonesia thus pose a clear and
269 present threat to humans.

270



■ Indonesian Human H5N1 cases
■ Human H5N1 cases in the world

271

272 **Figure 3. Human H5N1 cases in Indonesia**

273 Human H5N1 cases reported to the WHO are shown. The red bar indicates human H5N1
 274 cases detected in Indonesia, and the grey bar shows the number of human H5N1 cases
 275 worldwide. The numbers in the figure are the numbers of Indonesian human cases reported
 276 each year. The data are from a WHO report released on September 21, 2018 [23].

277

278

279

280

281

282

283

284

285

286 Various molecular changes have been identified that facilitate avian influenza virus
287 infection of humans. Three influenza virus proteins—PB2, HA, and non-structural protein
288 (NS1)—are recognized as major determinants of virulence, pathogenicity, and host range
289 restriction [10, 41, 42].

290 The HA protein mediates virus attachment and the fusion of the viral and
291 endosomal membranes [1]. The receptor-binding specificity of the HA protein plays an
292 important role in host range restriction. In general, avian influenza viruses bind preferentially
293 to sialic acid linked to galactose by an α 2,3-linkage (Sia α 2,3Gal), whereas human
294 influenza viruses have higher affinity for Sia α 2,6Gal [43-45]. Acquisition of Sia α 2,6Gal
295 recognition capability is thought to be essential for avian influenza viruses to possess
296 pandemic potential and transmit readily among humans [46, 47].

297 The PB2 protein is a component of the viral polymerase complex along with PB1,
298 PA, and NP. Among many amino acid mutations, PB2-627, PB2-701, and PB2-591 are
299 recognized as major determinants of pathogenicity and host range restriction [48-50].

300 Despite the current circulation of HPAI H5N1 viruses among poultry in Indonesia
301 and human H5N1 cases being continuously reported until 2017, there are few epidemiological
302 reports on Indonesian HPAI H5N1 viruses. As of October, 2018, the latest efforts to

303 molecularly characterize circulating viruses were conducted on HPAI H5N1 viruses isolated
304 in 2012 and 2013 [51, 52]. Little is known about the recent Indonesian HPAI H5N1 viruses,
305 including their potential to become endemic or cause global pandemics.

306 With the aim to elucidate the current situation with respect to HPAI H5N1 virus
307 circulation in Indonesia, our lab conducted epidemiological surveillance of poultry and swine
308 in Indonesia from 2010 through 2016. We isolated HPAI H5N1 viruses from collected
309 samples and characterized them, including assessing their human epidemic and pandemic
310 potential.

311

312

313

314

315

316

317

318

319

320 **Results**

321 **Isolation of HPAI H5N1 viruses**

322 From 2010 through 2016, we conducted epizootic surveillance of HPAI viruses
323 of the H5N1 subtype among poultry and swine in Indonesia. From the 2,534 samples
324 collected, 39 HPAI H5N1 virus strains were isolated utilizing embryonated chicken eggs
325 (Table 2, Fig. 4). More than 50% of the samples were collected in East Java. To elucidate the
326 current situation regarding HPAI H5N1 virus circulation in Indonesia, we characterized 39 of
327 these HPAI H5N1 virus strains.

328

329

330

331

332

333

334

335

336

337 **Table 2. Collected field samples and HPAI H5N1 virus strains isolated from them**

		Year						
		2010	2011	2012	2013	2014	2015	2016
		No. of (H5N1 swabs positive)	No. of (H5N1 swabs positive)	No. of (H5N1 swabs positive)	No. of (H5N1 swabs positive)	No. of (H5N1 swabs positive)	No. of (H5N1 swabs positive)	No. of (H5N1 swabs positive)
		503 (11)	147 (0)	411 (5)	56 (4)	854 (6)	124 (1)	439 (12)
Chicken	Total	233 (11)	95 (0)	4 (0)	40 (4)	615 (4)	82 (1)	372 (8)
	East Java	54 (1)	0 (0)	4 (0)	40 (4)	341 (4)	82 (1)	332 (8)
	Central Java	6 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	40 (0)
	West Java	38 (2)	85 (0)	0 (0)	0 (0)	83 (0)	0 (0)	0 (0)
	Kalimantan	34 (5)	0 (0)	0 (0)	0 (0)	191 (0)	0 (0)	0 (0)
	Sulawesi	40 (1)	10 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Sumatra	61 (1)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Duck	Total	9 (0)	50 (0)	2 (2)	12 (0)	214 (2)	27 (0)	55 (4)
	East Java	0 (0)	4 (0)	2 (2)	12 (0)	168 (1)	27 (0)	53 (4)
	Central Java	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (0)
	West Java	0 (0)	40 (0)	0 (0)	0 (0)	25 (0)	0 (0)	0 (0)
	Kalimantan	0 (0)	0 (0)	0 (0)	0 (0)	21 (1)	0 (0)	0 (0)
	Sulawesi	9 (0)	6 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Sumatra	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Quail	Total	0 (0)	1 (0)	3 (3)	4 (0)	0 (0)	0 (0)	0 (0)
	East Java	0 (0)	0 (0)	5 (5)	4 (0)	0 (0)	0 (0)	0 (0)
	Central Java	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	West Java	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Kalimantan	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Sulawesi	0 (0)	1 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Sumatra	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Other Avians	Total	0 (0)	1 (0)	0 (0)	0 (0)	25 (0)	15 (0)	12 (0)
	East Java	0 (0)	0 (0)	0 (0)	0 (0)	24 (0)	1 (0)	6 (0)
	Central Java	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6 (0)
	West Java	0 (0)	1 (0)	0 (0)	0 (0)	1 (0)	14 (0)	0 (0)
	Kalimantan	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Sulawesi	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Sumatra	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Swine	Total	261 (0)	0 (0)	400 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	East Java	201 (0)	0 (0)	190 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Central Java	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	West Java	36 (0)	31 (0)	210 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Kalimantan	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Sulawesi	0 (0)	91 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Sumatra	24 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

338

339 Listed in the table are the animal species and locations from which swab samples were
 340 collected, as well as the HPAI H5N1 virus strains isolated from those samples.

341


342

343

344

345

346



347

348 **Figure 4. Map of Indonesia**

349 Colored area shows the provinces where sampling for H5N1 virus was conducted between
 350 2010 and 2016; West Java (yellow), Central Java (red), East Java (orange), Sumatra (green),
 351 Kalimantan (blue) and Sulawesi (pink).

352

353

354

355

356

357

358

359

360

361

362 **Phylogenetic analysis of the HA and PB2 genes**

363 The nucleotide sequences of the eight segments of the isolated HPAI H5N1 virus
364 strains were analyzed by using the Sanger sequencing. To investigate the evolution of HPAI
365 H5N1 viruses in Indonesia between 2010 and 2016, phylogenetic trees of the eight viral
366 segments' genes of the 39 strains from our surveillance were constructed by using the
367 Neighbor-Joining method and MEGA 7 (Fig. 5A-H) [53-57]. Phylogenetic analysis of the
368 HA genes revealed that the 39 H5N1 virus strains were classified into two subclades, clade
369 2.1.3 and clade 2.3.2.1d (Fig. 5A) [58, 59]. Clade 2.1.3 virus strains had been circulating in
370 Indonesia since 2003 [34, 35], and 16 H5N1 virus strains from our surveillance, which were
371 isolated between 2010 and 2013, belonged to clade 2.1.3. The remaining 23 H5N1 virus
372 strains were classified into clade 2.3.2.1d [59], which has been circulating in Indonesia since
373 2012 [51]. In our surveillance, after 2014, all H5N1 virus strains belonged to clade 2.3.2.1d,
374 and no H5N1 virus strain belonging to clade 2.1.3 was identified.

375 Phylogenetic analysis of the NA, PB1, PA, NP, M, and NS genes revealed the same
376 pattern as that observed with HA; the isolated H5N1 virus strains being classified into two
377 subgroups corresponding to either clade 2.1.3 or clade 2.3.2.1d (Fig5. B, D-H).

378 Phylogenetic analysis of the PB2 genes of our 35 H5N1 virus strains revealed the
379 formation of three distinct sub-clusters (Fig. 5C). One sub-cluster comprised clade 2.1.3
380 strains, and the other two sub-clusters contained clade 2.3.2.1d strains. One sub-cluster of the
381 clade 2.3.2.1d strains included strains isolated between 2013 and 2016, whereas the other
382 clade 2.3.2.1d sub-cluster consisted of six strains of clade 2.3.2.1d virus collected at the same
383 live bird market on the same day in March, 2016. NCBI nucleotide BLAST analysis revealed
384 that these six strains' PB2 genes were 99% identical to another three Indonesian H5N1
385 viruses isolated in 2016: *A/chicken/Lamongan/04160418/2016*,
386 *A/chicken/Sukoharjo/04160454/2016*, and *A/chicken/Pati/04160433/2016*. The BLAST
387 analysis also revealed that these six strains' PB2 genes were 93%–94% identical to the PB2
388 genes of the following non-H5N1 viruses: *A/duck/Mongolia/47/2001* (H7N1),
389 *A/duck/Shimane/188/1999* (H1N1), *A/mallard/Jiangxi/7376/2003* (H6N2),
390 *A/duck/Malaysia/F118-08-04/2004* (H5N2), and *A/environment/Korea/W152/2006* (H7N7).
391 In the phylogenetic tree of PB2 genes, three clade 2.3.2.1d Indonesian HPAI H5N1 strains
392 with PB2 reassortment already listed above (*A/chicken/Pati/04160433/2016*,
393 *A/chicken/Sukoharjo/04160454/2016*, and *A/chicken/Lamongan/04160418/2016*) were
394 located in the vicinity of these six strains.

395 In addition to the 39 isolated H5N1 strains, there were several reassortant
396 Indonesian H5N1 viruses reported in the databases. Three clade 2.1.3 strains (A/muscovy
397 duck/East Java/SB29/2012, A/muscovy duck East Java/LM47/2012, and A/chicken/East
398 Java/BP21/2012) possessed reassortant PB2, PB1, and NS segments, as previously reported
399 [52]. Phylogenetic analysis also revealed that reassortment between clade 2.1.3 and clade
400 2.3.2.1d had already occurred in Indonesia in 2016, which, to our knowledge, has not been
401 reported. Two clade 2.3.2.1d strains isolated in 2016, A/chicken/Kuningan/08160178-
402 003/2016 and A/chicken/Majalengka/08160070-001/2016, possessed PB1, PA, NP, HA, and
403 NA segments belonging to clade 2.3.2.1d, but their PB2, M, and NS segments belonged to
404 clade 2.1.3.

405 These findings suggest that reassortment of viral segments has sporadically
406 occurred among both clade 2.1.3 and clade 2.3.2.1d H5N1 virus strains in Indonesia since at
407 least 2012 [52].


408

409


410

411

A. HA




B. NA




Clade 2.3.2.1d

Clade 2.1.3

C. PB2




D. PB1




415

416


E. PA



F. NP




G. M



419

420

H. NS



421
422
423

424 **Figure 5. Phylogenetic trees of the eight gene segments of Indonesian H5N1 virus strains**
425 Phylogenetic trees of the HA (A), NA (B), PB2 (C), PB1 (D), PA (E), NP (F), M (G), and NS
426 (H) genes of Indonesian H5N1 virus strains were constructed by using the Neighbor-Joining
427 method and MEGA 7. The trees were rooted to A/goose/Guangdong/1/1996. Virus strains
428 colored in yellow indicate strains isolated during our surveillance activities between 2010 and
429 2016.

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444 **Replication efficiency in cultured cells**

445 To assess the replicative ability of the isolated viruses in human respiratory cells,
446 we compared the growth properties of 24 HPAI H5N1 viruses at an MOI of 0.0002 in A549
447 cells incubated at either 33°C or 37°C. The replication efficiency of the clade 2.1.3 viruses
448 differed among the strains (Fig. 6A, C). In contrast, clade 2.3.2.1d strains grew to a moderate
449 degree without significant differences in replication efficiency among the strains (Fig. 6B, D).
450 All 23 viruses replicated well in DF-1 cells incubated at 39°C (Figure 7A–C).

451

452

453

454

455

456


457

458


459

460

A. clade 2.1.3 (33°C)




B. clade 2.3.2.1d (33°C)




461

462

C. clade 2.1.3 (37°C)



D. clade 2.3.2.1d (37°C)




463


464 **Figure 6. Virus growth in A549 cells incubated at 33°C and 37°C**

465 A549 cells were infected with clade 2.1.3 and clade 2.3.2.1d strains at an MOI of 0.0002 and
 466 then incubated at either 33°C or 37°C for 96 hours. The growth of clade 2.1.3 strains at 33°C
 467 (A) and 37°C (C), and the growth of clade 2.3.2.1d strains at 33°C (B) and 37°C (D) are
 468 shown. The data presented are the mean \pm s.d. of triplicate experiments. The detection limit of
 469 this experiment is 1 \log_{10} PFU/ml.

A. clade 2.1.3 and clade 2.3.2.1d (39°C)




B. clade 2.3.2.1d in 2016 (39°C)



470

471

C. clade 2.1.3 in 2010 (39°C)



472

473 **Figure 7. Virus growth in DF-1 cells at 39°C**

474 Viral growth in DF-1 cells was analyzed by infecting the cells with virus at an MOI of 0.0002
475 and then incubated them at 39°C for 96 hours. Three independent experiments were
476 conducted; shown is the growth property analysis of clade 2.1.3 and clade 2.3.2.1d strains
477 isolated between 2010 and 2015 (A), of clade 2.3.2.1d strains isolated in 2016 (B), and of
478 additional clade 2.1.3 strains isolated in 2010 (C). A/chicken/East Java/UT521/2010 was
479 included as a reference strain, which showed similar growth properties in all three
480 experiments. The data presented are the mean \pm s.d. of triplicate experiments. The detection
481 limit of this experiment is 1 \log_{10} PFU/ml.

482

483

484

485

486

487

488

489

490


491 We also analyzed the replicative ability of H5N1 viruses in normal human
492 bronchial epithelial (NHBE) cells (Figure 8A, B). Monolayers of NHBE cells were cultured
493 and differentiated at the air-liquid interface, and then infected with three H5N1 virus strains,
494 A/chicken/South Kalimantan/UT521/2010 (clade 2.1.3), A/chicken/East
495 Kalimantan/UT498/2010 (clade 2.1.3), and A/chicken/East Java/UT376/2014 (clade 2.3.2.1d)
496 at a viral concentration of 1000 PFU/well. A/California/04/2009 (H1N1 pdm09) virus was
497 also used as a representative human influenza virus. A/California/04/2009 replicated
498 efficiently in NHBE cells incubated at both 33°C and 37°C. In contrast, the three H5N1
499 viruses showed inferior replicative efficiency in NHBE cells compared to
500 A/California/04/2009, especially when incubated at 33°C. There was no significant difference
501 in viral replication efficiency between A/chicken/South Kalimantan/UT521/2010 and
502 A/chicken/East Java/UT376/2014. A/chicken/East Kalimantan/UT498/2010 replicated
503 similarly to A/chicken/South Kalimantan/UT521/2010 and A/chicken/East Java/UT376/2014
504 at 37°C, but little viral replication was observed at 33°C.

505


506

507

A. 33°C



B. 37°C



508

509 **Figure 8. Virus growth in NHBE cells incubated at 33°C and 37°C**

510 Differentiated NHBE cells were infected with A/chicken/East Kalimantan/UT498/2010 (clade
511 2.1.3), A/chicken/South Kalimantan/UT521/2010 (clade 2.1.3), A/chicken/East
512 Java/UT376/2014 (clade 2.3.2.1d), and A/California/04/2009 (H1N1 pdm09) at a viral
513 concentration of 1000 PFU/well, and then incubated at either 33°C (A) or 37°C (B) for 96
514 hours. The data presented are the mean \pm s.d. of triplicate experiments. The detection limit of
515 this experiment is 1 log₁₀PFU/ml.


516 **Pathogenicity in BALB/c mice**

517 To examine viral virulence in mammalian hosts, 6-week-old female BALB/c mice
518 were intranasally inoculated with H5N1 viruses at a concentration of 1×10^3 PFU, and body
519 weight changes and the mortality of the inoculated mice were recorded for 12 days (Fig. 9A-
520 D). The pathogenicity of the clade 2.1.3 viruses differed among the strains, and the mortality
521 rate of the BALB/c mice ranged from 0% to 75% (Fig. 9A, B). The clade 2.1.3 strains
522 possessing high replication efficiency in A549 cells (i.e., A/chicken/South
523 Kalimantan/UT521/2010 and A/quail/East Java/UALm01/2012) (Fig. 6A, B) also showed
524 high pathogenicity in BALB/c mice. In contrast, all clade 2.3.2.1d virus strains caused a
525 uniform decrease in body weight and a mortality rate of 100%, except for A/chicken/East
526 Java/UT167/2016 (Fig. 9C, D). A/chicken/East Java/UT167/2016 belonged to clade 2.3.2.1d,
527 but possessed a PB2 segment that is different from other clade 2.3.2.1d viruses (reassortant
528 PB2 segment from hereafter) and lacked the three PB2 mammalian-adaptive amino acids (i.e.,
529 PB2-147T-339T-588T) [60]. BALB/c mice infected with A/chicken/East Java/UT167/2016
530 showed little body weight change and their mortality rate was 25%.



531

532

A. clade 2.1.3




B. clade 2.1.3





533

534

C. clade 2.3.2.1d



D. clade 2.3.2.1d



535

536 **Figure 9. Pathogenicity in BALB/c mice**

537 6-week-old female BALB/c mice were intranasally inoculated with 1×10^3 PFU/animal of
 538 H5N1 virus strains, and their body weight change and survival rate were observed for 12
 539 days. Body weight change (A) and survival rate (B) of mice infected with clade 2.1.3 viruses,
 540 and body weight change (C) and survival rate (D) of mice infected with clade 2.3.2.1d viruses
 541 are shown. The values for body weight change are the mean \pm s.d. of live BALB/c mice.

542 **Mammalian-adaptive amino acid mutations in the PB2 protein of clade 2.3.2.1d strains**

543 Sequence analysis of PB2 genes revealed that clade 2.3.2.1d strains possessed a set
544 of three amino acids known to increase virulence in mammalian hosts: PB2-147T, -339T, and
545 -588T [60]. These three PB2 amino acids, originally found in H5N1 strains from Viet Nam,
546 increase viral polymerase activity and replication efficiency in mammalian cells, and also
547 enhance pathogenicity in mice [60]. However, the corresponding amino acids of the six
548 strains (A/chicken/East Java/UT167/2016, A/chicken/East Java/UT167C/2016,
549 A/chicken/East Java/UT168/2016, A/chicken/East Java/UT170/2016, A/chicken/East
550 Java/UT173/2016, A/chicken/East Java/UT173C/2016) with a reassortant PB2 segment were
551 PB2-147I, 339K, and 588A. None of the isolated virus strains possessed the well known
552 mammalian-adaptive amino acid mutations PB2-591K, -627K, or -701N [48-50].

553

554 **Viral polymerase activity**


555 Viral polymerase activity is an important determinant of viral pathogenicity and
556 host-range specificity. To assess the viral polymerase activity of the isolated H5N1 virus
557 strains, a mini-replicon assay in A549 cells and DF-1 cells was performed on seven H5N1
558 virus strains (three strains belonging to clade 2.1.3, and four strains to clade 2.3.2.1d).

559 A/Puerto Rico/8/34 (H1N1) (PR8) was also included in the analysis as a mammalian strain
560 (Fig. 10A-C). Among the analyzed virus strains including PR8, the difference in viral
561 polymerase activity in DF-1 cells incubated at 39°C was less than two fold. In A549 cells,
562 Indonesian H5N1 viruses possessed lower viral polymerase activity compared with that of
563 PR8, and this difference was more pronounced when the A549 cells were incubated at 33°C.
564 Clade 2.3.2.1d strains showed increased viral polymerase activity in A549 cells compared
565 with that of clade 2.1.3 strains, especially at 33°C. Among the clade 2.1.3 strains,
566 A/chicken/East Java/UT14/2013, isolated in 2013, possessed higher viral polymerase activity
567 in A549 cells than A/chicken/South Kalimantan/UT521/2010 or A/chicken/South
568 Sulawesi/UT541/2010. As to clade 2.3.2.1d strains, A/chicken/East Java/UT17/2013 and
569 A/chicken/East Java/UT64/2016 showed similar viral polymerase activity in A549 cells.
570 However, the clade 2.3.2.1d strains A/chicken/East Java/UT167/2016 and A/chicken/East
571 Java/UT173/2016, which have a reassortant PB2 segment, showed low viral polymerase
572 activity in A549 cells, similar to that of clade 2.1.3 strains.

573

574

575



576

577 **Figure 10. Viral polymerase activity**

578 A549 cells and DF-1 cells were transfected with 0.1 μ g each of the pCAGGS constructs
 579 encoding PB2, PB1, PA, NP, firefly luciferase, and Renilla luciferase. A549 cells were
 580 incubated at 33°C for 48 hours (A), or at 37°C for 24 hours (B), and DF-1 cells were
 581 incubated at 39°C for 24 hours (C); then, the mini-replicon assay was performed. The data
 582 presented are the mean \pm s.d. of triplicate experiments.

583 **Amino acid mutations in the HA protein of clade 2.1.3 and clade 2.3.2.1d strains**


584 Sequencing of the HA genes of the isolated viruses revealed multiple amino acid
585 mutations located around the receptor binding site. Among the clade 2.1.3 strains,
586 A/chicken/South Kalimantan/UT521/2010 and A/chicken/South Sulawesi/UT541/2010
587 possessed HA-137A and HA-193R, which are known to increase receptor binding affinity for
588 human-type sialic acid-linked galactose (Sia α 2,6Gal) [46, 61, 62]. A/chicken/South
589 Kalimantan/UT521/2010 and A/chicken/South Sulawesi/UT541/2010 also harbored unique
590 amino acid mutations (appearing in less than 40% of virus strains belonging to clade 2.1.3)
591 inside and around the receptor binding site (HA-144N, -187D, and -188A) (Fig. 11A). Clade
592 2.3.2.1d strains possessed the following previously reported mammalian-adaptive amino acid
593 mutations: HA-101N, -137A, -159N, -160A, and -193R [46, 61-64]. Clade 2.3.2.1d strains
594 also harbored unique amino acid mutations (appearing in less than 40% of virus strains
595 belonging to clade 2.3.2.1d) inside and around the receptor binding site (HA-120R, 145P, -
596 193K, and -222R) (Fig. 11B). Clade 2.3.2.1d strains have lost the glycosylation site at HA-
597 158, which is also known to increase human-type receptor binding affinity [46, 62, 65].

598


599

600

A. clade 2.1.3



B. clade 2.3.2.1d



● mammalian-adaptive amino acid ● unique amino acid

601

602

603 **Figure 11. Characteristic amino acids around the HA receptor binding site on the**
604 **structural model of HA trimer**

605 A structural model of the HA trimer was created by PyMOL using protein data obtained from
606 the Protein Data Bank (ID: 4KTH) [66]. Among amino acids of isolated Indonesian H5N1
607 viruses belonging to clade 2.1.3 (A) or clade 2.3.2.1d (B), the previously reported
608 mammalian-adaptive amino acids are colored in red, while unique amino acids are colored in
609 yellow. The amino acid HA-101N was located on the surface of internal side of HA trimer on
610 the model, thus was not shown in the figure. All the amino acids' positions are described in
611 H3 numbering.

612

613

614

615

616

617

618

619

620

621

622

623


624

625 **HA receptor binding assay**

626 To evaluate the receptor binding properties of the HA of recent Indonesian H5N1
627 virus strains, I performed a receptor binding assay on seven H5N1 virus strains - three clade
628 2.1.3 strains (A/chicken/South Kalimantan/UT521/2010, A/chicken/South
629 Sulawesi/UT541/2010, and A/chicken/East Java/UT14/2013) and four clade 2.3.2.1d strains
630 (A/chicken/East Java/UT17/2013, A/chicken/East Java/UT64/2016, A/chicken/East
631 Java/UT167/2016, and A/chicken/East Java/UT173/2016). Despite amino acid mutations
632 around the HA receptor binding site, all seven Indonesian H5N1 virus strains recognized Sia
633 α 2,3Gal, but did not bind to Sia α 2,6Gal (Figure 12A-G).

634

635



636

637 **Figure 12. HA receptor binding assay**

638 The binding of each virus strain to Sia α 2,3Gal (red) or Sia α 2,6Gal(blue) was analyzed.

639 Analyzed virus strains are as follows: A/chicken/South Kalimantan/UT521/2010 (UT521)

640 (A), A/chicken/South Sulawesi/UT541/2010 (UT541) (B), A/chicken/East Java/UT14/2013

641 (UT14) (C), A/chicken/East Java/UT17/2013 (UT17) (D), A/chicken/East Java/UT64/2016

642 (UT64) (E), A/chicken/East Java/UT167/2016 (UT167) (F), and A/chicken/East

643 Java/UT173/2016 (UT173) (G). A/Vietnam/1203/2004 (VN1203) (H5N1) bound to Sia α

644 2,3Gal (pink), and A/Kawasaki/173/2001 (K173) (H1N1) bound to Sia α 2,6Gal (green)

645 served as controls. All virus strains bound to Sia α 2,3Gal, but did not bind to Sia α 2,6Gal.

646

647 **Discussion**

648 During our surveillance activities in Indonesia between 2010 and 2016, HPAI
649 H5N1 virus strains were constantly isolated from poultry and waterfowl. During this
650 timeframe, HPAI H5N1 virus strains were also listed on databases such as the influenza virus
651 research (IVR) and global initiative on sharing all influenza data (GISAID) databases.

652 Therefore, it can be stated that HPAI H5N1 viruses are constantly circulating in poultry and
653 waterfowl in Indonesia.

654 Clade 2.1.3 strains had been circulating in Indonesia since 2003 [34, 36, 38]. After
655 the emergence of clade 2.3.2.1d strains in 2012, both clade 2.1.3 and clade 2.3.2.1d strains
656 were isolated between 2012 and 2013, suggesting co-circulation of these two different H5N1
657 subclades in Indonesia during that period [51].

658 During our surveillance, only clade 2.3.2.1d virus strains were isolated after 2014.
659 As of October 29, 2018, the HA genes of 36 HPAI H5N1 virus strains, which were isolated
660 between 2014 and 2018, were listed on the IVR and GISAID databases. Of these 36 virus
661 strains, 31 were isolated from avian hosts, and five were isolated from humans. Among the 31
662 isolated from avian hosts, only two strains belong to clade 2.1.3; the latest clade 2.1.3 strain
663 was isolated in 2016, in Deliserdang, Northern Sumatra.

664 Clade 2.3.2.1d strains are suspected to have been introduced into Indonesia in 2012
665 via an unknown route [67]. In the phylogenetic tree of HA genes, Indonesian clade 2.3.2.1d
666 strains are located in close proximity to clade 2.3.2.1c strains isolated in Viet Nam between
667 2012 and 2017 (Fig. 5A). NCBI nucleotide BLAST analysis of clade 2.3.2.1d strains,
668 A/duck/East Java/UADM53/2012, and A/chicken/East Java/UT17/2013 revealed multiple
669 H5N1 strains isolated in Viet Nam in 2012 and 2013 with 99% identity.

670 Our surveillance data and the databases possess sampling bias and, therefore,
671 cannot stand alone to make an assertive argument. That being said, the possibility exists that
672 clade 2.3.2.1d virus strains have become dominant among poultry in Indonesia since their
673 introduction to Indonesia in 2012. Our characterization analysis revealed no significant
674 difference in virus replication efficiency or in viral polymerase activity in DF-1 cells between
675 clade 2.1.3 strains and clade 2.3.2.1d strains. Our data thus cannot provide an explanation for
676 the suspected dominance of clade 2.3.2.1d strains over clade 2.1.3 strains in poultry.

677 The HA receptor binding assay showed that neither clade 2.1.3 nor clade 2.3.2.1d
678 Indonesian H5N1 viruses have acquired the ability to bind to α 2,6-linked
679 sialylglycopolymers, which is essential for efficient infection and transmission among
680 humans [44-46]. Human influenza virus strains are reported to preferentially bind to longer

681 α 2,6-linked sialylglycopolymers; however, only short unbranched sialylglycopolymers were
682 used in our HA receptor binding assay [68, 69]. Hence, we cannot exclude the possibility that
683 the HA of Indonesian H5N1 viruses has acquired some level of human-type receptor binding
684 capability. Our characterization analysis revealed that clade 2.3.2.1d strains possess high
685 pathogenicity in BALB/c mice, resulting in 100% mortality when inoculated at a viral
686 concentration of 1×10^3 PFU per animal. This high virulence likely resulted from the presence
687 of three PB2 amino acids (PB2-47T, -339T, and -588T), as previously reported [60]. The viral
688 polymerase activity of the clade 2.3.2.1d strains in A549 cells was also increased compared
689 with that of clade 2.1.3 strains. While the replication efficiency of clade 2.1.3 strains varied
690 among strains infecting A549 cells, clade 2.3.2.1d strains showed moderate replication
691 efficiency in these cells at both 33°C and 37°C, without significant differences among the
692 virus strains.

693 When discussing characterization differences between clade 2.1.3 and clade
694 2.3.2.1d strains, we are limited by sampling biases, especially with respect to the sampling
695 locations. The analyzed clade 2.1.3 strains were collected in various areas of Indonesia
696 between 2010 and 2013, mostly from chickens. In contrast, the analyzed clade 2.3.2.1d strains
697 were collected mostly in East Java between 2013 and 2016, and their hosts were either

698 chickens or ducks. Therefore, it is possible that the uniform viral characteristics, high
699 virulence in BALB/c mice, and moderate replication efficiency in A549 cells of the observed
700 clade 2.3.2.1d strains are limited to such strains circulating in East Java, and do not represent
701 clade 2.3.2.1d strains from other areas of Indonesia.

702 It is difficult to assess the infectivity and virulence of Indonesian H5N1 virus strains
703 in humans. Human H5N1 cases in Indonesia have been regularly reported to the WHO, but
704 the number of cases has drastically decreased since 2010; only five human cases have been
705 reported since 2014 (Fig. 3). Interestingly, among the five H5N1 virus strains isolated from
706 these human hosts, four strains belonged to clade 2.1.3, and only one strain, isolated in 2017,
707 belonged to clade 2.3.2.1d. In Viet Nam, where clade 2.3.2.1c strains are circulating, the last
708 human cases of H5N1 infection were reported in 2014.

709 Our analysis of the Indonesian clade 2.3.2.1d strains revealed that they possess
710 strong virulence in BALB/c mice and that their viral polymerase activity is higher in A549
711 cells than that of clade 2.1.3 strains. Clade 2.3.2.1d strains can replicate to a moderate degree
712 in A549 cells, but their replication efficiency was not superior to that of some clade 2.1.3
713 strains despite having higher polymerase activity in A549 cells. The dissociation between the
714 observed viral characteristics and the decrease in reported human H5N1 cases might be due to

715 the inability of clade 2.3.2.1d strains to efficiently infect human hosts. Another possibility is
716 that the clade 2.3.2.1d viruses establish subclinical or mild infections that are overlooked, and
717 the number of infected patients is actually underestimated [70-72].

718 During our surveillance, we detected HPAI H5N1 virus clade 2.3.2.1d strains with
719 reassortant PB2 segments of unknown origin. The identified reassortant virus strains did not
720 possess higher replication efficiency or pathogenicity in mammalian hosts compared to other
721 clade 2.3.2.1d strains currently circulating in Indonesia. However, the possibility of human-
722 adapted HPAI H5N1 virus strains emerging through reassortment remains. This risk warrants
723 the establishment of further surveillance of HPAI viruses in Indonesia.

724 According to reported epidemiological data, the number of human H5N1 infection
725 cases in Indonesia has remained low for the past five years, after the emergence of the clade
726 2.3.2.1d strains. The clade 2.3.2.1d strains, however, were revealed to possess moderate
727 replication capability in A549 cells, and their polymerase activity in A549 cells is high
728 compared to the previously dominant clade 2.1.3 strains. Moreover, clade 2.3.2.1d strains are
729 highly virulent in BALB/c mice. The possibility cannot be dismissed that Indonesian H5N1
730 virus strains might acquire efficient infectivity and transmissibility to humans through viral
731 reassortment and amino acid mutations. Continuation and reinforcement of HPAI surveillance

732 in Indonesia is crucial for prevention and early detection of such human-adapted HPAI H5N1
733 viruses.

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749 **Chapter 2: Amino acid substitutions in the PB2 protein of an H5N1 avian influenza**
750 **virus enhance its replication efficiency and pathogenicity in mammalian hosts.**

751

752 **Introduction**

753 HPAI H5N1 viruses have been enzootic among poultry worldwide since 1996, and
754 860 human cases of HPAI H5N1 infection have been reported to the WHO as of October,
755 2018, with a high mortality rate [19, 22, 23]. However, so far, human HPAI H5N1 cases have
756 been limited to those with close contact with infected poultry, and it is suspected that efficient
757 human-to-human transmission of HPAI H5N1 has not yet taken place in nature. In order for
758 HPAI H5N1 viruses to overcome host range restriction and induce epidemics or global
759 pandemics, they need to acquire mammalian-adaptive qualities such as efficient infection and
760 replication in humans, human-to-human transmissibility, and evasion of human immune
761 responses to viral infection [2, 10].

762 Among the influenza A viral proteins, PB2 is considered a major determinant of
763 virulence, pathogenicity, and host range restriction [10]. The PB2 protein is an essential
764 component of the viral polymerase complex, together with the PB1, PA, and NP proteins.
765 Various mammalian-adaptive mutations of PB2 have been identified, including PB2-627K,

766 PB2-701N, and PB2-591K [48-50]. HPAI H5N1 virus strains possessing such mammalian-
767 adaptive PB2 segments are already circulating worldwide. For example, HPAI H5N1 clade
768 2.2.1 viruses currently circulating in Egypt typically possess PB2-627K [73-75]. HPAI H5N1
769 clade 2.3.2.1c viruses circulating in Viet Nam and clade 2.3.2.1d viruses currently circulating
770 in Indonesia possess three amino acids in PB2, namely PB2-47T, -339T, and -588T, which
771 together confer high viral polymerase activity and virulence in mammalian hosts [60].

772 Our characterization analysis of Indonesian HPAI H5N1 virus strains isolated
773 between 2010 and 2016 revealed two genetically closely related strains belonging to clade
774 2.1.3 with different replication efficiency and pathogenicity in mammalian hosts:
775 *A/chicken/South Kalimantan/UT521/2010* (UT521) and *A/chicken/South*
776 *Sulawesi/UT541/2010* (UT541) (Fig. 13). UT521 possessed high replication efficiency in
777 A549 cells and high pathogenicity in BALB/c mice (Fig. 6A, 6C, 9A, 9B). In contrast, UT541
778 possessed low replication efficiency and low pathogenicity. Sequencing analysis identified 36
779 different amino acids between UT521 and UT541 (Table 3). The amino acid sequences of the
780 Indonesian clade 2.1.3 strains listed in the IVR and GISAID databases were also analyzed.
781 Amino acids prevalent among more than 40% of Indonesian clade 2.1.3 strains were defined
782 as major amino acids, whereas amino acids, of which less than 10% of Indonesian clade 2.1.3

783 strains are possessed, were defined as unique amino acids. In Table 3, the unique amino acids
784 are colored in yellow. Our goal was to identify the viral factors responsible for the observed
785 differences in viral character between the two strains by using reassortant and mutant HPAI
786 H5N1 viruses.

787

788

789

790

791

792

793

794


795

796

797

798

799



800

801 **Figure 13. Phylogenetic tree of the HA genes of Indonesian H5N1 strains**

802 The phylogenetic tree of the HA genes was constructed using the neighboring-joining method
 803 and MEGA 7. The tree was rooted to A/goose/Guangdong/1/96. UT521 (colored in red) and
 804 UT541 (colored in green), which both belong to clade 2.1.3, are located close together in the
 805 phylogenetic tree of the HA genes.

806

807

808

809

810

811 **Table 3. Amino acids differences between UT521 and UT541**

Virus	HA							NA						NS1					NS2
	86	129	140	214	373	511	528	32	50	53	111	120	143	53	126	188	207	210	36
A/chicken/SouthKalimantan/UT521/2010	T	L	N	T	R	I	A	I	N	K	T	L	M	D	R	Q	F	S	K
A/chicken/SouthSulawesi/UT541/2010	N	S	S	A	K	V	S	L	S	N	I	M	V	N	K	R	L	P	E

Virus	PB2					PB1			PA				M2				
	109	292	369	447	758	117	331	339	294	396	535	602	20	31	58	90	95
A/chicken/SouthKalimantan/UT521/2010	A	A	K	L	T	T	K	V	A	D	Q	A	I	S	E	Y	E
A/chicken/SouthSulawesi/UT541/2010	V	T	N	Q	I	A	E	I	D	N	H	V	T	G	G	H	A

major amino acid
 unique amino acid

812

813 Nucleotide sequences were analyzed by direct sequencing. Thirty-six amino acids were
 814 different between UT521 and UT541. Unique amino acids are colored in yellow in the table.

815 Both UT521 and UT541 possessed unique amino acid of PB2 at position 369, and the major
 816 amino acid was arginine. All the amino acids' positions are described in H5 numbering.

817

818

819

820

821

822

823


824 **Results**

825 **Generation by reverse genetics and characterization of A/chicken/South**

826 **Kalimantan/UT521/2010 and A/chicken/South Sulawesi/UT541/2010**

827 UT521 and UT541 were generated by using reverse genetics [27]. RG1 indicates
828 the reverse genetics strain of UT521, and RG17 indicates the reverse genetics strain of
829 UT541. All virus strains with RG in the name were generated by means of reverse genetics.
830 To test whether there were any differences between the wild-type virus strains and the reverse
831 genetics-generated virus strains, their viral growth capability in A549 and DF-1 cells was
832 analyzed. There was no significant difference in replication efficiency between the wild-type
833 and reverse genetics-generated virus strains (Figure 14A-C). MLD₅₀ values in BALB/c mice
834 were also determined; while both the wild-type and reverse genetics-generated strains of
835 UT541 had MLD₅₀ values higher than 1x10⁶ PFU/animal, RG1, the reverse genetics-
836 generated strain of UT521, had an MLD₅₀ value of 1x10^{3.8} PFU/animal, in contrast to the
837 wild-type UT521 strain's MLD₅₀ value of 1x10^{2.8} PFU/animal. Together, these results
838 demonstrate that the reverse genetics-generated strains possessed similar viral properties to
839 those of the wild-type strains and were therefore suitable for further analysis.

840



841

842 **Figure 14. Viral replication efficiency of wild-type and reverse genetics-generated**
 843 **viruses in A549 and DF-1 cells**

844 The viral replication efficiency of wildtype and reverse genetics-generated strains of UT521
 845 and UT541 was analyzed in A549 cells incubated at 33°C (A) and at 37°C (B), and in DF-1
 846 cells incubated at 39°C (C). Wild-type virus strains are indicated as UT521 (WT) and UT541
 847 (WT). RG1 represents the reverse genetics-generated strain of UT521, and RG17 represents
 848 the reverse genetics-generated strain of UT541. The data presented are the mean ± s.d. of
 849 triplicate experiments.

850

851

852

853

854 **The effect of viral surface glycoproteins and the polymerase complex on viral replication**
855 **efficiency in A549 cells**

856 To elucidate which of the eight viral RNA segments is responsible for the
857 difference in replication efficiency between UT521 and UT541, reassortant viruses were
858 produced by reverse genetics, and their growth properties in A549 cells incubated at 33°C
859 and 37°C were analyzed.

860 First, the eight viral RNA segments were categorized into three groups: the
861 polymerase complex consisting of the PB2, PB1, PA, and NP segments; the surface
862 glycoprotein group consisting of the HA and NA segments, and the remaining group
863 consisting of the M and NS segments. Viruses with different combinations of the three groups
864 were generated by reverse genetics and their growth properties were analyzed in A549 and
865 DF-1 cells.

866 In A549 cells incubated at 37°C, viruses possessing the surface glycoproteins of
867 UT521 (RG 1, RG18, RG21, and RG22) showed high replication efficiency (Fig. 15B).
868 Among the virus strains possessing the surface glycoproteins of UT521, virus strains with the
869 polymerase complex of UT521 (RG1 and RG22) showed higher replication efficiency than
870 those with the polymerase complex of UT541 (RG18 and RG21). The enhancing effect of

871 possessing both the polymerase complex and the surface glycoproteins of UT521 was more
872 pronounced in A549 cells incubated at 33°C than at 37°C (Fig. 15A). All of the generated
873 reassortant viruses grew well in DF-1 cells incubated at 39°C (Fig. 15C).

874

875

876

877

878

879

880

881

882

883



884

885



886

887

A. A549 (33°C)




B. A549 (37°C)



UT521 UT541

C. DF-1 (39°C)



889

890 **Figure 15. Effect of the viral polymerase complex and surface glycoproteins on viral**
 891 **replication in A549 cells**

892 Viral replication efficiency of reassortant virus strains was analyzed in A549 cells incubated
 893 at 33°C (A) and 37°C (B), and in DF-1 cells incubated at 39°C (C). The data presented are
 894 the mean \pm s.d. of triplicate experiments.

895

896

897

898

899

900

901 **The effect of the NA segment on viral replication efficiency in A549 cells**


902 When the effect of the surface glycoproteins HA and NA on viral growth was
903 analyzed, it was revealed that virus strains with the NA segment of UT541 possessed lower
904 replication efficiency in A549 cells incubated at 37°C (RG17, RG20, RG33 and RG34),
905 compared to virus strains with the NA segment of UT521 (Fig. 16A). All of the generated
906 reassortant viruses grew well in DF-1 cells incubated at 39°C (Fig. 16B).

907 The NA segments of UT521 and UT541 differ by six amino acids located at
908 positions 32, 50, 53, 111, 120, and 143 (Table 3). Viruses with single amino acid mutations
909 introduced into the NA segment were generated by reverse genetics. Viral growth property
910 analysis revealed that virus strains possessing unique amino acids of UT541 strain (RG17,
911 RG33, RG48, RG52, RG53, RG54, RG77, RG78 and RG79), namely NA-32-L, NA-111I,
912 and NA-120M, showed lower replication efficiency in A549 cells compared to virus strains
913 possessing either major amino acids or unique amino acids of UT521 strain (Fig. 17A). All of
914 the generated reassortant viruses grew well in DF-1 cells incubated at 39°C (Fig. 17B).

915

916

917




918

919 **Figure 16. Effect of the NA segment on viral replication in A549 cells**

920 Viral replication efficiency of reassortant virus strains was analyzed in A549 cells incubated
 921 at 37°C (A) and in DF-1 cells incubated at 39°C (B). The data presented are the mean \pm s.d.
 922 of triplicate experiments.

923

924



925

926 **Figure 17. Viral replication efficiency of mutant NA strains in A549 cells**

927 Viral replication efficiency of virus strains with mutant NA segments was analyzed in A549
 928 cells incubated at 37°C (A) and in DF-1 cells incubated at 39°C (B). Unique amino acids are
 929 colored in yellow. The data presented are the mean ± s.d. of triplicate experiments.

930


931 **The effect of the PB2 segment on viral replication efficiency in A549 cells**

932 The growth property analysis of the reassortant viruses in A549 cells incubated at
933 33°C revealed that both the viral polymerase complex and the surface glycoproteins of
934 UT521 are required for high viral replication efficiency (Fig. 15A, B). In addition, the NA
935 segment of UT521 was found to be essential for high viral replication efficiency in A549 cells
936 (Fig. 16A).

937 When the effect of the polymerase complex (i.e., the PB2, PB1, PA, and NP
938 segments) on viral growth was analyzed, it was revealed that virus strains with the PB2
939 segment of UT521 possessed higher replication efficiency in A549 cells incubated at 33°C
940 (RG1, RG26, RG27 and RG36), compared to virus strains with the PB2 segment of UT541
941 (Fig. 18A). Viral growth property analysis of virus strains with reassortant NA and PB2
942 segments revealed that both the NA and PB2 segments of UT521 are essential for efficient
943 viral replication in A549 cells incubated at 33°C (RG1 and RG70) (Fig. 19A). All of the
944 generated reassortant viruses grew well in DF-1 cells incubated at 39°C (Fig. 18B, 19B). We
945 conducted further analysis focusing on the PB2 segment.

946

947




948


949 **Figure 18. Effect of the PB2 segment on viral replication in A549 cells at 33°C**

950 Viral replication efficiency of reassortant virus strains was analyzed in A549 cells incubated
 951 at 33°C (A) and in DF-1 cells incubated at 39°C (B). The data presented are the mean \pm s.d.
 952 of triplicate experiments.

A. A549 (33°C)



B. DF-1 (39°C)



953

954 Figure 19. Effect of the NA and PB2 segments on viral replication in A549 cells at 33°C
 955 Viral replication efficiency of reassortant virus strains was analyzed in A549 cells incubated
 956 at 33°C (A) and in DF-1 cells incubated at 39°C (B). The data presented are the mean ± s.d.
 957 of triplicate experiments.

958

959 The PB2 segments of UT521 and UT541 differ by five amino acids located at
960 positions 109, 292, 369, 447, and 758 (Table 3). Viruses with single amino acid mutations
961 introduced into the PB2 segment were generated by reverse genetics. Analysis of the growth
962 property of the generated mutant viruses in A549 cells revealed the following findings. When
963 introduced into the polymerase complex of UT521, PB2-A109V (exchange from unique to
964 major amino acid) resulted in the greatest decrease in viral replication efficiency (RG1 and
965 RG59), followed by PB2-T758I (exchange from unique to major amino acid) (RG1 and
966 RG58) (Fig. 20A). When introduced into the polymerase complex of UT541, PB2-V109A
967 (exchange from major to unique amino acid) resulted in the greatest increase in viral
968 replication efficiency (RG18 and RG64), followed by PB2-I758T (exchange from major to
969 unique amino acid) (RG18 and RG63) (Fig. 20A). From the findings above, two unique
970 amino acids of UT521, PB2-109A and PB2-758T, were identified to confer higher replication
971 efficiency in A549 cells incubated at 33°C (Fig. 20A). Simultaneous introduction of amino
972 acid mutations into both PB2 loci revealed a synergistic effect on viral replication efficiency
973 (RG80 and RG81) (Fig. 21A). All of the reassortant and mutant virus strains produced by
974 reverse genetics replicated well in DF-1 cells incubated at 39°C (Fig. 20B, 21B).

975 When plotted in a structural model of the polymerase complex (Protein Data Bank
976 ID: 4WSB) using PyMOL (DeLano Scientific, San Carlos, CA, USA), PB2-109A was located
977 on the surface of the polymerase complex (Fig. 22). The function of PB2-109A/V has not
978 been reported and remains unknown. PB2-758T is reported to be part of the nuclear
979 localization signal (NLS), and could not be plotted on the structural model because the
980 published crystal structure of the polymerase complex did not include the NLS region [76].

981

982

983

984

985

986



987

988

989

990

991



■ UT521 ■ UT541 ■ unique amino acid

992



993 Figure 20. Viral replication efficiency of mutant PB2 strains in A549 cells

994 Viral replication efficiency of virus strains with mutant PB2 segments was analyzed in A549



995 cells incubated at 33°C (A) and in DF-1 cells incubated at 39°C (B). The data presented are

996 the mean ± s.d. of triplicate experiments.

A. A549 (33°C)



B. DF-1 (33°C)



■ UT521 ■ UT541


997

998 **Figure 21. Effect of PB2-109A and PB2-758T on viral replication in A549 cells at 33°C**

999 Viral replication efficiency of PB2 mutant virus strains was analyzed in A549 cells incubated

1000 at 33°C (A) and in DF-1 cells incubated at 39°C (B). The data presented are the mean ± s.d.

1001 of triplicate experiments.



1002

1003 **Figure 22. PB2-109A/V location on the structural model of the polymerase complex**

1004 A structural model of the polymerase complex was created by PyMOL using protein data
 1005 obtained from the Protein Data Bank (ID: 4WSB) [76]. The PB2 protein is colored in white,
 1006 the PB1 protein in wheat, and the PA protein in black. PB2-109A/V is shown on the surface
 1007 of the polymerase complex by the red spheres. PB2-758T/I could not be plotted on the model
 1008 because of the model is lacking in data around the region.

1009

1010

1011

1012

1013

1014

1015

1016

1017 **The effect of PB2 amino acid mutations on virus pathogenicity in BALB/c mice**

1018 Viral MLD₅₀ values were obtained in order to evaluate the effect of two PB2 amino
1019 acid mutations on virus pathogenicity in BALB/c mice (Table 4). The introduction of the
1020 unique amino acid PB2-109A into the polymerase complex of UT541 resulted in greater
1021 enhancement of pathogenicity in BALB/c mice compared to the introduction of PB2-758T. In
1022 contrast, the introduction of either of the major amino acids PB2-109V or PB2-758I into the
1023 polymerase complex of UT521 conferred similar diminishing effects on pathogenicity in
1024 BALB/c mice. The simultaneous introduction of PB2-109A and PB2-758T into the
1025 polymerase complex of UT541, or the introduction of PB2-109V and PB2-758I into the
1026 polymerase complex of UT521 had a synergistic effect on pathogenicity in BALB/c mice.

1027 To investigate viral replication in BALB/c mice, mice were inoculated with virus at
1028 a concentration of 1×10^3 PFU/animal, and organs were harvested on days 3 and 6 post-
1029 inoculation to determine virus titers in the organs (Table 4, Fig. 23A-I). Wild-type UT521
1030 was notable for its replication capability in both respiratory and non-respiratory organs,
1031 indicating that wild-type UT521 possesses an invasive trait. In the lungs, wild-type UT521,
1032 RG1 (UT521 reverse genetics-generated strain), RG36, and RG81 showed higher replication
1033 efficiency than the rest of the analyzed viruses, indicating that the combination of PB2-109A

1034 and PB2-758T is important for high BALB/c pathogenicity. Among the non-respiratory
1035 organs analyzed, RG1 replication was identified in the spleen and heart, RG36 in the spleen,
1036 and RG81 in the brain (Fig. 23A-I).

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051 **Table 4. BALB/c MLD₅₀ values for PB2 reassortant and mutant viruses**

Virus	PB2	PB1	PA	NP	HA	NA	M	NS	BALB/c MLD ₅₀ [PFU/animal]	Virus Titer in Lungs [log ₁₀ PFU/g]					
										Day3			Day6		
										#1	#2	#3	#1	#2	#3
UT521(WT)									1x10 ^{2.8}	6.67	6.38	6.51	7.97	6.54	6.48
RG1									1x10 ^{3.8}	3.80	2.90	3.34	5.83	5.30	5.56
RG59	V								1x10 ^{4.5}	2.85	2.90	-	2.78	-	-
RG58		I							1x10 ^{4.7}	3.93	3.15	3.40	3.00	3.15	3.18
RG80	V	I							> 1x10 ⁶	2.30	2.48	2.60	2.30	3.32	2.48
RG24									1x10 ^{5.5}	3.00	-	-	-	-	3.85
RG18									> 1x10 ⁶	2.48	2.78	2.78	2.60	4.92	2.70
RG64	A								1x10 ^{4.5}	3.34	2.78	3.04	3.58	4.61	5.78
RG63		T							1x10 ^{6.0}	2.30	3.54	3.23	3.83	4.59	4.62
RG81	A	T							1x10 ^{4.5}	4.46	4.41	3.23	5.48	4.49	5.93
RG36									1x10 ^{4.0}	5.53	5.89	5.84	6.45	6.07	6.10
RG17									> 1x10 ⁶	2.30	2.30	2.30	2.60	2.00	2.00
UT541(WT)									> 1x10 ⁶	3.04	3.11	2.90	2.95	3.43	3.43

--: detection limit <2 [log₁₀PFU/g]

■ **UT521** ■ **UT541**


1052

1053 MLD₅₀ values in BALB/c mice and viral growth in mouse organs were analyzed. PB2-109A
 1054 and PB2-758T conferred high virulence in BALB/c mice. Wild-type UT521 replicated well in
 1055 the lungs and in non-respiratory organs. RG1, RG36, and RG81 replicated well in the lungs.
 1056 These three strains also grew in some non-respiratory organs. The detection limit was 2
 1057 log₁₀PFU/g.

1058

1059

1060



1061

1062 **Figure 23. Viral replication in BALB/c mouse organs**

1063 BALB/c mice were intranasally inoculated with H5N1 virus strains at a concentration of
 1064 1×10^3 PFU/animal; organs were harvested on days 3 and day 6 post-inoculation, and a plaque
 1065 assay was conducted in MDCK cells. The figures show virus titers in the lungs (A), nasal
 1066 turbinate (B), trachea (C), brain (D), heart (E), liver (F), spleen (G), kidney (G) and colon (I)
 1067 on day 3 and day 6. The detection limit was $2 \log_{10}$ PFU/g.

1068 **Mini-replicon assay**


1069 To evaluate the effect of the identified PB2 amino acid mutations on viral
1070 polymerase activity, a mini-replicon assay was performed in A549 and DF-1 cells. Although
1071 the viral replication efficiency in A549 cells of the virus strain possessing the polymerase
1072 complex of UT521 (RG1) was higher than that of the virus strain with the polymerase
1073 complex of UT541 (RG17), the viral polymerase activity in A549 cells was higher with the
1074 UT541 polymerase complex than with the UT521 polymerase complex (Fig. 24). The
1075 respective introduction of the unique PB2 amino acids PB2-109A and PB2-758T into the
1076 UT541 polymerase complex increased the viral polymerase activity in A549 cells. The
1077 respective introduction of the major PB2 amino acids PB2-109V and PB2-758I into the
1078 UT521 polymerase complex had little effect on the polymerase activity in A549 cells. There
1079 was no significant difference in viral polymerase activity in DF-1 cells among the evaluated
1080 viruses.

1081

1082

1083

1084



1085
 1086
 1087
 1088
 1089
 1090
 1091
 1092
 1093
 1094
 1095
 1096
 1097
 1098

Figure 24. The effect of PB2-109A and PB2-758T on viral polymerase activity

Viral polymerase activity was measured by use of a mini-replicon assay. The polymerase activity of UT521 was set to 100%. UT541 showed higher polymerase activity compared to UT521 in A549 cells incubated at 33°C or 37°C. The respective introduction of the unique PB2 amino acids PB2-109A and PB2-758T into UT541 increased polymerase activity in A549 cells. The respective introduction of the major amino acids PB2-109V and PB2-758I into UT521 had little effect on polymerase activity in A549 cells. No significant difference in polymerase activity was identified among the analyzed strains in DF-1 cells. The data presented are the mean ± s.d. of triplicate experiments.

1099 **PB2 nuclear localization**

1100 PB2-758I is known to be a part of the NLS [77]. To evaluate the effect of PB2
1101 amino acid mutations on nuclear import, pCAGGS plasmid DNA encoding wild-type and
1102 mutant PB2 protein was transfected into A549 cells incubated at 33°C. The transfected A549
1103 cells were fixed and stained with a mouse monoclonal antibody against PB2 protein (PB2-
1104 18/1) and observed using a laser-scanning microscope. Nuclear accumulation of the PB2
1105 protein was observed from 4 hours post-transfection. There was no appreciable difference in
1106 the timing or pattern of the nuclear accumulation of PB2 protein (Fig. 25 A-F).

1107

1108

1109

1110


1111

1112

1113


1114

1115




PB2

UT521 UT541



PB2 ¹⁰⁹
 V


UT521 UT541



pCAGGS-UT521(PB2-758I)

PB2 ⁷⁵⁸


UT521 UT541



pCAGGS-UT541

PB2


UT521 UT541



pCAGGS-UT541(PB2-109A)

PB2¹⁰⁹

UT521 UT541



pCAGGS-UT541(PB2-758T)

PB2⁷⁵⁸

UT521 UT541

1119 **Figure 25. Viral PB2 protein nuclear localization**

1120 pCAGGS plasmid DNA encoding wild-type and mutant PB2 protein (0.25 μ g) was
1121 transfected into A549 cells incubated at 33°C (A-F). The transfected A549 cells were fixed
1122 and stained with a mouse monoclonal antibody against PB2 and observed by using a laser-
1123 scanning microscope.

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139 **vRNP intracellular localization**

1140 To investigate the effect of the PB2 amino acid mutations PB2-109A and PB2-758T
1141 on viral intracellular localization, A549 cells were infected with reassortant virus strains at an
1142 MOI of 100 and incubated at 33°C for 24 hours. The A549 cells were then fixed and stained
1143 with the mouse anti-WSN NP 3/1 monoclonal antibody, which was previously reported to
1144 recognize vRNP complexes [78]. The vRNP intracellular localization in infected A549 cells
1145 was observed by using a laser-scanning microscope. In order to conduct the experiment in the
1146 BSL2 facility, reassortant viruses possessing the HA and NA segments of PR8 and the rest of
1147 the genes from the H5N1 backbone were generated by using reverse genetics.

1148 Immunofluorescence analysis of the reassortant viruses revealed that the vRNP first
1149 appeared in the cytoplasm, then, 6 hours post-infection, nuclear localization of the vRNP was
1150 observed. Fluorescence associated with the vRNP in the cytoplasm gradually intensified, and
1151 at 24 hours post-infection, the vRNP was mostly located in the cytoplasm. No significant
1152 difference was observed between the analyzed virus strains (Fig. 26).

1153 The replication efficiency of the recombinant mutant virus strains in A549 cells
1154 incubated at 33°C was analyzed, at an MOI of 10 (Fig. 27). Although the enhancing effect of
1155 PB2-109A and PB2-758T on viral growth could still be observed, the difference in virus titers

1156 among the analyzed virus strains was small compared with the viral growth analysis of the
1157 H5N1 strains that did not bear HA and NA segments from PR8, infected at the low MOI of
1158 0.0002 (Fig. 21A, Fig. 27).

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169


1170

1171

1172

1173

A




RG1(PR8)



UT521 **UT541** **PR8**

1174

B




RG18(PR8) PB2 PB1 PA NP HA NA M NS

UT521 UT541 PR8

1175


C



RG24(PR8) PB2 PB1 PA NP HA NA M NS

■ UT521 ■ UT541 ■ PR8

1176



1177

1178 **Figure 26. Immunofluorescence analysis of the intracellular localization of vRNP**


1179 A549 cells were infected with reassortant virus strains bearing the HA and NA segments of
 1180 PR8 at an MOI of 100 and incubated at 33°C for 24 hours. The A549 cells were then fixed at
 1181 different time points and stained with a vRNP-recognizing monoclonal antibody (anti-WSN
 1182 NP 3/1) and observed by using a laser-scanning microscope.

1183

1184

1185

1186



1187

1188 **Figure 27. Replication efficiency of recombinant mutant virus strains in A549 cells**
 1189 **incubated at 33°C**

1190 Recombinant viruses possessing an H5N1 backbone with mutant PB2 segments and HA and
 1191 NA segments from PR8 were generated by using reverse genetics. For example, the virus
 1192 strain possessing the UT521 backbone with the HA and NA segments of PR8 is indicated as
 1193 RG1(PR8) in the figure above. The viral replication efficiency of the generated recombinant
 1194 mutant virus strains was analyzed in A549 cells incubated at 33°C, at an MOI of 10, utilizing
 1195 virus titers measured in MDCK cells and supplementation with 1 μ g/mL of 6- (1-
 1196 tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin. The data presented
 1197 are the mean \pm s.d. of triplicate experiments.

1198

1199

1200

1201

1202 **Discussion**

1203 In this study, we found that two unique amino acids of the PB2 segment, PB2-109A
1204 and PB2-758T, confer high replication efficiency in A549 cells, especially at 33°C, and high
1205 pathogenicity in BALB/c mice. Although we attempted to elucidate the mechanism by which
1206 these amino acids enhance virulence, we were unable to do so.

1207 The two unique PB2 amino acids were identified and analyzed using reassortant
1208 and mutant viruses generated by reverse genetics. Although the replication efficiency in A549
1209 and DF-1 cells did not differ between the wild-type H5N1 viruses and their counterpart
1210 reverse genetics-generated viruses, a difference in pathogenicity in mice was observed
1211 between the wild-type UT521 virus and the reverse genetics-generated UT521 virus. Wild-
1212 type UT521 virus possessed higher mouse pathogenicity compared to the reverse genetics-
1213 generated strain of UT521 (RG1), as assessed by measuring MLD₅₀ values. Moreover, wild-
1214 type UT521 showed replicative ability in non-respiratory organs, whereas the replication of
1215 RG1 was limited to the respiratory organs, heart, and spleen. Sequencing of all of the viral
1216 genomes of RG1 revealed no nucleotide mutation from wild-type UT521. The reason for this
1217 observed phenomenon remains unclear, but it has been speculated that a quasispecies state of

1218 wild-type UT521 might confer higher virulence and an invasive trait in infected BALB/c mice
1219 [79, 80].

1220 Unique amino acids in the NA segment of UT541 were responsible for its low
1221 replication efficiency in A549 cells. NA-32L is located in the stalk region, and NA-111I and
1222 NA-120L are thought to be located in the head domain, based on analyses of the NA 3D
1223 model. The mechanism by which these amino acids lower the viral replication efficiency in
1224 A549 cells is unknown.

1225 Two unique PB2 amino acids of UT521, PB2-109A and PB2-758T, were found to
1226 enhance virulence in mammalian hosts. The degree of enhancement, however, differed
1227 between PB2-109A and PB2-758T. Briefly, the introduction of the unique amino acid PB2-
1228 109A conferred greater enhancement of viral replication efficiency in A549 cells incubated at
1229 33°C and of BALB/c mouse pathogenicity compared to the introduction of PB2-758T.
1230 Similarly, the introduction of the major amino acid PB2-109V resulted in greater
1231 diminishment of viral replication and pathogenicity compared to the introduction of PB2-
1232 758I, but its effect on BALB/c mouse pathogenicity was less pronounced. Together, the two
1233 amino acids had a synergistic effect.

1234 The replication efficiency in A549 cells incubated at 33°C was greater for viruses
1235 possessing the polymerase complex of UT521 compared to those with the polymerase
1236 complex of UT541. However, the mini-replicon assay revealed that the viral polymerase
1237 activity of UT521 was considerably lower than that of UT541. This inconsistency between
1238 viral replication efficiency and polymerase activity might indicate that UT521 uses a
1239 replication efficiency-enhancing mechanism that does not involve viral polymerase activity,
1240 or that UT541 is more sensitive to inhibition of viral replication. PB2-109A and PB2-758T
1241 each increased the polymerase activity when introduced into the polymerase complex of
1242 UT541, which is consistent with their enhancement of viral replication efficiency and
1243 pathogenicity. However, although the introduction of the major amino acids PB2-109V and
1244 PB2-758I into the polymerase complex of UT521 reduced the replication efficiency in A549
1245 cells and virus pathogenicity in BALB/c mice, the introduction of those major amino acids
1246 had little effect on viral polymerase activity. These findings indicate that the enhancing
1247 effects of PB2-109A and PB2-758T on viral replication efficiency and pathogenicity result
1248 from a mechanism other than viral polymerase activity modification.

1249 Since PB2-758T/I is reported to be part of the NLS, pCAGGS plasmid DNA
1250 encoding the viral PB2 protein was transfected into A549 cells for immunofluorescence

1251 analysis. The analysis of mutant PB2 protein, however, revealed no difference in nuclear
1252 localization efficiency among the analyzed PB2 protein [76]. The effect of PB2-758T/I on the
1253 observed differences in viral replication efficiency and pathogenicity could, therefore, not be
1254 attributed to the efficiency of viral PB2 protein nuclear localization.

1255 The function of PB2-109A/V has not yet been reported in the literature. PB2 is a
1256 major component of the viral polymerase complex along with PB1, PA, and NP, functioning
1257 in viral replication, cap-snatching and viral transcription, and the formation of newly
1258 synthesized vRNP complexes. Newly synthesized vRNP complexes are assembled and
1259 packaged into progeny virions [1, 76]. To evaluate whether PB2-109A/V and PB2-758T/I
1260 have any involvement in the viral replication cycle, immunofluorescence analysis of the
1261 intracellular localization of the vRNP complexes was conducted. This analysis, however, did
1262 not reveal any significant differences in the intracellular localization patterns of the analyzed
1263 PB2 reassortant viruses. I suspect that vRNP observed in the nucleus represents accumulated
1264 newly synthesized vRNP complexes. Analysis of the intracellular localization of vRNP
1265 complexes originating from infected viruses has been attempted by inhibiting new viral
1266 protein production using cycloheximide or 5,6-dichloro-1- β -D-ribofuranosyl-benzimidazole
1267 (DRB) [81-84]. In this study, the addition of cycloheximide or DRB, however, prevented the

1268 nuclear localization of the vRNP complexes and the intracellular localization of incoming
1269 vRNP complexes could not be evaluated (data not shown). In the immunofluorescence
1270 analysis of the intracellular localization of vRNP complexes, redistribution of the vRNP
1271 complexes into the cytoplasm was observed, which likely represented the nuclear export of
1272 newly synthesized vRNP complexes. No significant difference was observed at this stage of
1273 the viral cell cycle among the analyzed PB2 reassortant viruses.

1274 On a structural model of the polymerase complex, PB2-109A/V was plotted on the
1275 surface. The location of PB2-109A/V on the model was adjacent to where PB2 protein
1276 interacts with PB1 protein, so it is possible that PB2-109A/V plays a role in polymerase
1277 complex stability. PB2-109A/V might also interact with viral or host factors. The plotted
1278 location of PB2-109A/V on the polymerase complex was not in the vicinity of areas reported
1279 to be involved in cap-snatching or vRNA replication activity [76].

1280 The viral PB2 segment is also reported to interact with the host immune system [85-
1281 87]. Therefore, it is possible that PB2-109A and PB2-758T provide H5N1 viruses with the
1282 ability to escape from host immune responses, which in turn provides higher replication
1283 efficiency and pathogenicity in mammalian hosts. Measurement of interferon- β or other host

1284 immune system mediators would help further elucidate the functions of the amino acid

1285 mutations PB2-109A and PB2-758T.

1286

1287 **Conclusion**

1288 Our epidemiological surveillance of poultry and swine in Indonesia between 2010
1289 and 2016 revealed that two sub-clades of viruses, clade 2.1.3 and clade 2.3.2.1d, were
1290 circulating in Indonesia. Our data, together with information from databases, suggest the
1291 possibility that clade 2.3.2.1d strains have become dominant in Indonesian poultry.
1292 Characterization analysis revealed that clade 2.3.2.1d strains possess mammalian-adaptive
1293 traits, including high viral polymerase activity and moderate replication capability in human
1294 lung epithelial cells, as well as high virulence in BALB/c mice. Our findings support the
1295 continued surveillance of HPAI H5N1 viruses in Indonesia, in order to detect the emergence
1296 of viruses with endemic or pandemic capability.

1297 Through a virological analysis of two genetically closely related viruses with
1298 different replication efficiency and pathogenicity in mammalian hosts, we identified two
1299 amino acid mutations in the viral PB2 protein, PB2-109A and PB2-758T, that enhance viral
1300 replication efficiency in human lung epithelial cells and pathogenicity in BALB/c mice.
1301 Although the mechanism by which these two PB2 mutations enhance virulence in mammalian
1302 hosts has not yet been elucidated, our findings are of value for assessing the risk of avian-to-
1303 human transmission of highly pathogenic H5N1 avian influenza field isolates.

1304 **Acknowledgements**

1305 I would like to express my greatest appreciation for the keen insights and passionate
1306 instruction of Prof. Yoshihiro Kawaoka, Division of Virology, Department of Microbiology
1307 and Immunology, Institute of Medical Science, University of Tokyo and Department of
1308 Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison.

1309 I am deeply grateful for the great mentorship, profound patience, and ceaseless
1310 encouragement from Dr. Shinya Yamada, Division of Virology, Department of Microbiology
1311 and Immunology, Institute of Medical Science, University of Tokyo.

1312 I would like to express my gratitude for the critical devotion to our collaborative
1313 research and warm hospitality of Prof. Chairul A. Nidom, Avian Influenza Research Center
1314 Laboratory, Professor Nidom Foundation, and Faculty of Veterinary Medicine, Universitas
1315 Airlangga, Surabaya, Indonesia.

1316 I owe my gratitude to Dr. Kiyoko Iwatsuki-Horimoto, Division of Virology,
1317 Department of Microbiology and Immunology, Institute of Medical Science, University of
1318 Tokyo, for her instruction and support both in the laboratory and in the field.

1319 I would like to thank Drs. Yuko Sakai-Tagawa, Masaki Imai, Maki Kiso, and Seiya
1320 Yamayoshi, Division of Virology, Department of Microbiology and Immunology, Institute of
1321 Medical Science, University of Tokyo for their technical assistance and advice.

1322 I would also like to express my appreciation to Dr. Reina Yamaji, World Health
1323 Organization, Geneva, and to Reviany V. Nidom, Setyarina Indrasari, Kuncoro P. Santoso,
1324 and the other laboratory staff and students of the Avian Influenza Research Center
1325 Laboratory, Professor Nidom Foundation, and Faculty of Veterinary Medicine, Universitas
1326 Airlangga, Surabaya, Indonesia for their hard work and sincere dedication to epidemiological
1327 surveillance in Indonesia.

1328 This work was supported by the NIAID-funded Center for Research on Influenza
1329 Pathogenesis (CRIP) (HHSN272201400008C).

1330

1331

1332

1333

1334

1335

1336 **References**

- 1337 1. Shaw, M. and P. Palese, *Orthomyxoviridae*, p 1151–1185. *Fields virology*. 2013,
1338 Lippincott Williams & Wilkins, Philadelphia, PA.
- 1339 2. Wright, P., G. Neumann, and Y. Kawaoka, *Orthomyxoviruses*. *Fields Virology*, eds
1340 Knipe DM, et al. 2013, Lippincott Williams & Wilkins, Philadelphia, PA).
- 1341 3. Osterhaus, A.D., G.F. Rimmelzwaan, B.E. Martina, T.M. Bestebroer, and R.A.
1342 Fouchier, *Influenza B virus in seals*. *Science*, 2000. **288**(5468): p. 1051-3.
- 1343 4. Bodewes, R., D. Morick, G. de Mutsert, N. Osinga, T. Bestebroer, S. van der Vliet,
1344 S.L. Smits, T. Kuiken, G.F. Rimmelzwaan, R.A. Fouchier, and A.D. Osterhaus,
1345 *Recurring influenza B virus infections in seals*. *Emerg Infect Dis*, 2013. **19**(3): p. 511-
1346 2.
- 1347 5. Jelley, L., A. Levy, Y.M. Deng, N. Spirason, J. Lang, I. Buettner, J. Druce, C. Blyth,
1348 P. Effler, D. Smith, and I.G. Barr, *Influenza C infections in Western Australia and*
1349 *Victoria from 2008 to 2014*. *Influenza Other Respir Viruses*, 2016. **10**(6): p. 455-461.
- 1350 6. Matsuzaki, Y., K. Sugawara, C. Abiko, T. Ikeda, Y. Aoki, K. Mizuta, N. Katsushima,
1351 F. Katsushima, Y. Katsushima, T. Itagaki, Y. Shimotai, S. Hongo, Y. Muraki, and H.
1352 Nishimura, *Epidemiological information regarding the periodic epidemics of*
1353 *influenza C virus in Japan (1996-2013) and the seroprevalence of antibodies to*
1354 *different antigenic groups*. *J Clin Virol*, 2014. **61**(1): p. 87-93.
- 1355 7. Atkinson, K.V., L.A. Bishop, G. Rhodes, N. Salez, N.R. McEwan, M.J. Hegarty, J.
1356 Robey, N. Harding, S. Wetherell, R.M. Lauder, R.W. Pickup, M. Wilkinson, and D.
1357 Gatherer, *Influenza C in Lancaster, UK, in the winter of 2014-2015*. *Sci Rep*, 2017. **7**:
1358 p. 46578.
- 1359 8. Su, S., X. Fu, G. Li, F. Kerlin, and M. Veit, *Novel Influenza D virus: Epidemiology,*
1360 *pathology, evolution and biological characteristics*. *Virulence*, 2017. **8**(8): p. 1580-
1361 1591.
- 1362 9. Hause, B.M., M. Ducatez, E.A. Collin, Z. Ran, R. Liu, Z. Sheng, A. Armien, B.
1363 Kaplan, S. Chakravarty, A.D. Hoppe, R.J. Webby, R.R. Simonson, and F. Li, *Isolation*
1364 *of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to*
1365 *human influenza C viruses*. *PLoS Pathog*, 2013. **9**(2): p. e1003176.
- 1366 10. Neumann, G., H. Chen, G.F. Gao, Y. Shu, and Y. Kawaoka, *H5N1 influenza viruses:*
1367 *outbreaks and biological properties*. *Cell Res*, 2010. **20**(1): p. 51-61.
- 1368 11. Horimoto, T. and Y. Kawaoka, *Influenza: lessons from past pandemics, warnings*
1369 *from current incidents*. *Nat Rev Microbiol*, 2005. **3**(8): p. 591-600.

- 1370 12. Neumann, G., T. Noda, and Y. Kawaoka, *Emergence and pandemic potential of*
1371 *swine-origin H1N1 influenza virus*. *Nature*, 2009. **459**(7249): p. 931-9.
- 1372 13. Tong, S., Y. Li, P. Rivaille, C. Conrardy, D.A. Castillo, L.M. Chen, S. Recuenco,
1373 J.A. Ellison, C.T. Davis, I.A. York, A.S. Turmelle, D. Moran, S. Rogers, M. Shi, Y.
1374 Tao, M.R. Weil, K. Tang, L.A. Rowe, S. Sammons, X. Xu, M. Frace, K.A. Lindblade,
1375 N.J. Cox, L.J. Anderson, C.E. Rupprecht, and R.O. Donis, *A distinct lineage of*
1376 *influenza A virus from bats*. *Proc Natl Acad Sci U S A*, 2012. **109**(11): p. 4269-74.
- 1377 14. Tong, S., X. Zhu, Y. Li, M. Shi, J. Zhang, M. Bourgeois, H. Yang, X. Chen, S.
1378 Recuenco, J. Gomez, L.M. Chen, A. Johnson, Y. Tao, C. Dreyfus, W. Yu, R.
1379 McBride, P.J. Carney, A.T. Gilbert, J. Chang, Z. Guo, C.T. Davis, J.C. Paulson, J.
1380 Stevens, C.E. Rupprecht, E.C. Holmes, I.A. Wilson, and R.O. Donis, *New world bats*
1381 *harbor diverse influenza A viruses*. *PLoS Pathog*, 2013. **9**(10): p. e1003657.
- 1382 15. Webster, R.G., W.J. Bean, O.T. Gorman, T.M. Chambers, and Y. Kawaoka, *Evolution*
1383 *and ecology of influenza A viruses*. *Microbiol Rev*, 1992. **56**(1): p. 152-79.
- 1384 16. Swayne, D.E. and D.L. Suarez, *Highly pathogenic avian influenza*. *Rev Sci Tech*,
1385 2000. **19**(2): p. 463-82.
- 1386 17. Horimoto, T. and Y. Kawaoka, *Pandemic threat posed by avian influenza A viruses*.
1387 *Clin Microbiol Rev*, 2001. **14**(1): p. 129-49.
- 1388 18. Horimoto, T. and Y. Kawaoka, *Reverse genetics provides direct evidence for a*
1389 *correlation of hemagglutinin cleavability and virulence of an avian influenza A virus*.
1390 *J Virol*, 1994. **68**(5): p. 3120-8.
- 1391 19. Xu, X., Subbarao, N.J. Cox, and Y. Guo, *Genetic characterization of the pathogenic*
1392 *influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin*
1393 *gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong*. *Virology*,
1394 1999. **261**(1): p. 15-9.
- 1395 20. Claas, E.C., A.D. Osterhaus, R. van Beek, J.C. De Jong, G.F. Rimmelzwaan, D.A.
1396 Senne, S. Krauss, K.F. Shortridge, and R.G. Webster, *Human influenza A H5N1 virus*
1397 *related to a highly pathogenic avian influenza virus*. *Lancet*, 1998. **351**(9101): p. 472-
1398 7.
- 1399 21. Subbarao, K., A. Klimov, J. Katz, H. Regnery, W. Lim, H. Hall, M. Perdue, D.
1400 Swayne, C. Bender, J. Huang, M. Hemphill, T. Rowe, M. Shaw, X. Xu, K. Fukuda,
1401 and N. Cox, *Characterization of an avian influenza A (H5N1) virus isolated from a*
1402 *child with a fatal respiratory illness*. *Science*, 1998. **279**(5349): p. 393-6.
- 1403 22. Health), O.T.W.O.f.A., *OIE Situation Report for Highly Pathogenic Avian Influenza*.
1404 2018.

- 1405 23. Organization), W.W.H. *Cumulative number of confirmed human cases for avian*
1406 *influenza A(H5N1) reported to WHO*. 2018 [cited 2018 25, October, 2018];
1407 Available from:
1408 [https://www.who.int/influenza/human_animal_interface/2018_09_21_tableH5N1.pdf?](https://www.who.int/influenza/human_animal_interface/2018_09_21_tableH5N1.pdf?ua=1)
1409 [ua=1](https://www.who.int/influenza/human_animal_interface/2018_09_21_tableH5N1.pdf?ua=1).
- 1410 24. Organization), W.W.H. *H5N1 highly pathogenic avian influenza: Timeline of major*
1411 *events*. 2014; Available from:
1412 [https://www.who.int/influenza/human_animal_interface/H5N1_avian_influenza_upda](https://www.who.int/influenza/human_animal_interface/H5N1_avian_influenza_update20141204.pdf)
1413 [te20141204.pdf](https://www.who.int/influenza/human_animal_interface/H5N1_avian_influenza_update20141204.pdf).
- 1414 25. Davis, A.S., D.S. Chertow, J.E. Moyer, J. Suzich, A. Sandouk, D.W. Dorward, C.
1415 Logun, J.H. Shelhamer, and J.K. Taubenberger, *Validation of normal human*
1416 *bronchial epithelial cells as a model for influenza A infections in human distal*
1417 *trachea*. *J Histochem Cytochem*, 2015. **63**(5): p. 312-28.
- 1418 26. Jakiela, B., R. Brockman-Schneider, S. Amineva, W.M. Lee, and J.E. Gern, *Basal*
1419 *cells of differentiated bronchial epithelium are more susceptible to rhinovirus*
1420 *infection*. *Am J Respir Cell Mol Biol*, 2008. **38**(5): p. 517-23.
- 1421 27. Neumann, G., T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D.R.
1422 Perez, R. Donis, E. Hoffmann, G. Hobom, and Y. Kawaoka, *Generation of influenza*
1423 *A viruses entirely from cloned cDNAs*. *Proc Natl Acad Sci U S A*, 1999. **96**(16): p.
1424 9345-50.
- 1425 28. Reed, L.J., *A simple method of estimating fifty per cent endpoints*. *Am J Hyg.*, 1938.
1426 **27**: p. 493-497.
- 1427 29. Yamayoshi, S., S. Yamada, S. Fukuyama, S. Murakami, D. Zhao, R. Uraki, T.
1428 Watanabe, Y. Tomita, C. Macken, G. Neumann, and Y. Kawaoka, *Virulence-affecting*
1429 *amino acid changes in the PA protein of H7N9 influenza A viruses*. *J Virol*, 2014.
1430 **88**(6): p. 3127-34.
- 1431 30. Niwa, H., K. Yamamura, and J. Miyazaki, *Efficient selection for high-expression*
1432 *transfectants with a novel eukaryotic vector*. *Gene*, 1991. **108**(2): p. 193-9.
- 1433 31. Lin, Y.P., X. Xiong, S.A. Wharton, S.R. Martin, P.J. Coombs, S.G. Vachieri, E.
1434 Christodoulou, P.A. Walker, J. Liu, J.J. Skehel, S.J. Gamblin, A.J. Hay, R.S. Daniels,
1435 and J.W. McCauley, *Evolution of the receptor binding properties of the influenza*
1436 *A(H3N2) hemagglutinin*. *Proc Natl Acad Sci U S A*, 2012. **109**(52): p. 21474-9.
- 1437 32. Kiso, M., K. Iwatsuki-Horimoto, S. Yamayoshi, R. Uraki, M. Ito, N. Nakajima, S.
1438 Yamada, M. Imai, E. Kawakami, Y. Tomita, S. Fukuyama, Y. Itoh, K. Ogasawara,
1439 T.J.S. Lopes, T. Watanabe, L.H. Moncla, H. Hasegawa, T.C. Friedrich, G. Neumann,

- 1440 and Y. Kawaoka, *Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in*
1441 *Immunosuppressed Cynomolgus Macaques*. J Infect Dis, 2017. **216**(5): p. 582-593.
- 1442 33. Yamayoshi, S., M. Watanabe, H. Goto, and Y. Kawaoka, *Identification of a Novel*
1443 *Viral Protein Expressed from the PB2 Segment of Influenza A Virus*. J Virol, 2016.
1444 **90**(1): p. 444-56.
- 1445 34. Network, T.W.H.O.G.I.P.S., *Evolution of H5N1 avian influenza viruses in Asia*.
1446 Emerg Infect Dis, 2005. **11**(10): p. 1515-21.
- 1447 35. Lam, T.T., C.C. Hon, O.G. Pybus, S.L. Kosakovsky Pond, R.T. Wong, C.W. Yip, F.
1448 Zeng, and F.C. Leung, *Evolutionary and transmission dynamics of reassortant H5N1*
1449 *influenza virus in Indonesia*. PLoS Pathog, 2008. **4**(8): p. e1000130.
- 1450 36. Li, K.S., Y. Guan, J. Wang, G.J. Smith, K.M. Xu, L. Duan, A.P. Rahardjo, P.
1451 Puthavathana, C. Buranathai, T.D. Nguyen, A.T. Estoepangestie, A. Chaisingh, P.
1452 Auewarakul, H.T. Long, N.T. Hanh, R.J. Webby, L.L. Poon, H. Chen, K.F.
1453 Shortridge, K.Y. Yuen, R.G. Webster, and J.S. Peiris, *Genesis of a highly pathogenic*
1454 *and potentially pandemic H5N1 influenza virus in eastern Asia*. Nature, 2004.
1455 **430**(6996): p. 209-13.
- 1456 37. Wibawa, H., D. Karo-Karo, E.S. Pribadi, A. Bouma, R. Bodewes, H. Vernooij,
1457 Diyantoro, A. Sugama, D.H. Muljono, G. Koch, F.S. Tjatur Rasa, and A. Stegeman,
1458 *Exploring contacts facilitating transmission of influenza A(H5N1) virus between*
1459 *poultry farms in West Java, Indonesia: A major role for backyard farms?* Prev Vet
1460 Med, 2018. **156**: p. 8-15.
- 1461 38. Takano, R., C.A. Nidom, M. Kiso, Y. Muramoto, S. Yamada, Y. Sakai-Tagawa, C.
1462 Macken, and Y. Kawaoka, *Phylogenetic characterization of H5N1 avian influenza*
1463 *viruses isolated in Indonesia from 2003-2007*. Virology, 2009. **390**(1): p. 13-21.
- 1464 39. Nidom, C.A., R. Takano, S. Yamada, Y. Sakai-Tagawa, S. Daulay, D. Aswadi, T.
1465 Suzuki, Y. Suzuki, K. Shinya, K. Iwatsuki-Horimoto, Y. Muramoto, and Y. Kawaoka,
1466 *Influenza A (H5N1) viruses from pigs, Indonesia*. Emerg Infect Dis, 2010. **16**(10): p.
1467 1515-23.
- 1468 40. Organization), W.W.H. *Influenza at the human-animal interface Summary and*
1469 *assessment, 25 July 2017 to 27 September 2017*. 2017 [25, October, 2018]; Available
1470 from:
1471 [http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA](http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_09_27_2017.pdf?ua=1)
1472 [_interface_09_27_2017.pdf?ua=1](http://www.who.int/influenza/human_animal_interface/Influenza_Summary_IRA_HA_interface_09_27_2017.pdf?ua=1).
- 1473 41. Neumann, G. and Y. Kawaoka, *Host range restriction and pathogenicity in the*
1474 *context of influenza pandemic*. Emerg Infect Dis, 2006. **12**(6): p. 881-6.

- 1475 42. Neumann, G., K. Shinya, and Y. Kawaoka, *Molecular pathogenesis of H5N1*
1476 *influenza virus infections*. Antivir Ther, 2007. **12**(4 Pt B): p. 617-26.
- 1477 43. Rogers, G.N. and J.C. Paulson, *Receptor determinants of human and animal influenza*
1478 *virus isolates: differences in receptor specificity of the H3 hemagglutinin based on*
1479 *species of origin*. Virology, 1983. **127**(2): p. 361-73.
- 1480 44. Auewarakul, P., O. Suptawiwat, A. Kongchanagul, C. Sangma, Y. Suzuki, K.
1481 Ungchusak, S. Louisirirothanakul, H. Lerdsamran, P. Pooruk, A. Thitithanyanont, C.
1482 Pittayawonganon, C.T. Guo, H. Hiramatsu, W. Jampangern, S. Chunsutthiwat, and P.
1483 Puthavathana, *An avian influenza H5N1 virus that binds to a human-type receptor*. J
1484 Virol, 2007. **81**(18): p. 9950-5.
- 1485 45. Suzuki, Y., *Sialobiology of influenza: molecular mechanism of host range variation of*
1486 *influenza viruses*. Biol Pharm Bull, 2005. **28**(3): p. 399-408.
- 1487 46. Mair, C.M., K. Ludwig, A. Herrmann, and C. Sieben, *Receptor binding and pH*
1488 *stability - how influenza A virus hemagglutinin affects host-specific virus infection*.
1489 Biochim Biophys Acta, 2014. **1838**(4): p. 1153-68.
- 1490 47. Yamada, S., Y. Suzuki, T. Suzuki, M.Q. Le, C.A. Nidom, Y. Sakai-Tagawa, Y.
1491 Muramoto, M. Ito, M. Kiso, T. Horimoto, K. Shinya, T. Sawada, M. Kiso, T. Usui, T.
1492 Murata, Y. Lin, A. Hay, L.F. Haire, D.J. Stevens, R.J. Russell, S.J. Gamblin, J.J.
1493 Skehel, and Y. Kawaoka, *Haemagglutinin mutations responsible for the binding of*
1494 *H5N1 influenza A viruses to human-type receptors*. Nature, 2006. **444**(7117): p. 378-
1495 82.
- 1496 48. Hatta, M., P. Gao, P. Halfmann, and Y. Kawaoka, *Molecular basis for high virulence*
1497 *of Hong Kong H5N1 influenza A viruses*. Science, 2001. **293**(5536): p. 1840-2.
- 1498 49. Li, Z., H. Chen, P. Jiao, G. Deng, G. Tian, Y. Li, E. Hoffmann, R.G. Webster, Y.
1499 Matsuoka, and K. Yu, *Molecular basis of replication of duck H5N1 influenza viruses*
1500 *in a mammalian mouse model*. J Virol, 2005. **79**(18): p. 12058-64.
- 1501 50. Yamada, S., M. Hatta, B.L. Staker, S. Watanabe, M. Imai, K. Shinya, Y. Sakai-
1502 Tagawa, M. Ito, M. Ozawa, T. Watanabe, S. Sakabe, C. Li, J.H. Kim, P.J. Myler, I.
1503 Phan, A. Raymond, E. Smith, R. Stacy, C.A. Nidom, S.M. Lank, R.W. Wiseman, B.N.
1504 Bimber, D.H. O'Connor, G. Neumann, L.J. Stewart, and Y. Kawaoka, *Biological and*
1505 *structural characterization of a host-adapting amino acid in influenza virus*. PLoS
1506 Pathog, 2010. **6**(8): p. e1001034.
- 1507 51. Dharmayanti, N.L., R. Hartawan, H. Wibawa, A. Balish, R. Donis, C.T. Davis, and G.
1508 Samaan, *Genetic characterization of clade 2.3.2.1 avian influenza A(H5N1) viruses,*
1509 *Indonesia, 2012*. Emerg Infect Dis, 2014. **20**(4): p. 671-4.

- 1510 52. Dharmayanti, N., S.W. Thor, N. Zanders, R. Hartawan, A. Ratnawati, Y. Jang, M.
 1511 Rodriguez, D.L. Suarez, G. Samaan, Pudjiatmoko, and C.T. Davis, *Attenuation of*
 1512 *highly pathogenic avian influenza A(H5N1) viruses in Indonesia following the*
 1513 *reassortment and acquisition of genes from low pathogenicity avian influenza A virus*
 1514 *progenitors*. Emerg Microbes Infect, 2018. **7**(1): p. 147.
- 1515 53. Kumar, S., G. Stecher, and K. Tamura, *MEGA7: Molecular Evolutionary Genetics*
 1516 *Analysis Version 7.0 for Bigger Datasets*. Mol Biol Evol, 2016. **33**(7): p. 1870-4.
- 1517 54. Kumar, S., M. Nei, J. Dudley, and K. Tamura, *MEGA: a biologist-centric software for*
 1518 *evolutionary analysis of DNA and protein sequences*. Brief Bioinform, 2008. **9**(4): p.
 1519 299-306.
- 1520 55. Saitou, N. and M. Nei, *The neighbor-joining method: a new method for reconstructing*
 1521 *phylogenetic trees*. Mol Biol Evol, 1987. **4**(4): p. 406-25.
- 1522 56. Felsenstein, J., *Confidence limits on phylogenies: an approach using the bootstrap*.
 1523 Evolution, 1985. **39**(4): p. 783-791.
- 1524 57. Tamura, K., M. Nei, and S. Kumar, *Prospects for inferring very large phylogenies by*
 1525 *using the neighbor-joining method*. Proc Natl Acad Sci U S A, 2004. **101**(30): p.
 1526 11030-5.
- 1527 58. World Health Organization/World Organisation for Animal, H.F. and H.N.E.W.G.
 1528 Agriculture Organization, *Revised and updated nomenclature for highly pathogenic*
 1529 *avian influenza A (H5N1) viruses*. Influenza Other Respir Viruses, 2014. **8**(3): p. 384-
 1530 8.
- 1531 59. Jiang, W., G. Hou, J. Li, C. Peng, S. Wang, and J. Chen, *Novel variants of clade*
 1532 *2.3.2.1 H5N1 highly pathogenic avian influenza virus in migratory waterfowl of*
 1533 *Hongze Lake*. Vet Microbiol, 2017. **198**: p. 99-103.
- 1534 60. Fan, S., M. Hatta, J.H. Kim, P. Halfmann, M. Imai, C.A. Macken, M.Q. Le, T.
 1535 Nguyen, G. Neumann, and Y. Kawaoka, *Novel residues in avian influenza virus PB2*
 1536 *protein affect virulence in mammalian hosts*. Nat Commun, 2014. **5**: p. 5021.
- 1537 61. Yang, Z.Y., C.J. Wei, W.P. Kong, L. Wu, L. Xu, D.F. Smith, and G.J. Nabel,
 1538 *Immunization by avian H5 influenza hemagglutinin mutants with altered receptor*
 1539 *binding specificity*. Science, 2007. **317**(5839): p. 825-8.
- 1540 62. Wang, W., B. Lu, H. Zhou, A.L. Suguitan, Jr., X. Cheng, K. Subbarao, G. Kemble,
 1541 and H. Jin, *Glycosylation at 158N of the hemagglutinin protein and receptor binding*
 1542 *specificity synergistically affect the antigenicity and immunogenicity of a live*
 1543 *attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets*. J Virol, 2010. **84**(13):
 1544 p. 6570-7.

- 1545 63. Su, Y., H.Y. Yang, B.J. Zhang, H.L. Jia, and P. Tien, *Analysis of a point mutation in*
1546 *H5N1 avian influenza virus hemagglutinin in relation to virus entry into live*
1547 *mammalian cells*. Arch Virol, 2008. **153**(12): p. 2253-61.
- 1548 64. Gao, Y., Y. Zhang, K. Shinya, G. Deng, Y. Jiang, Z. Li, Y. Guan, G. Tian, Y. Li, J.
1549 Shi, L. Liu, X. Zeng, Z. Bu, X. Xia, Y. Kawaoka, and H. Chen, *Identification of amino*
1550 *acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a*
1551 *mammalian host*. PLoS Pathog, 2009. **5**(12): p. e1000709.
- 1552 65. Imai, M., T. Watanabe, M. Hatta, S.C. Das, M. Ozawa, K. Shinya, G. Zhong, A.
1553 Hanson, H. Katsura, S. Watanabe, C. Li, E. Kawakami, S. Yamada, M. Kiso, Y.
1554 Suzuki, E.A. Maher, G. Neumann, and Y. Kawaoka, *Experimental adaptation of an*
1555 *influenza H5 HA confers respiratory droplet transmission to a reassortant H5*
1556 *HA/H1N1 virus in ferrets*. Nature, 2012. **486**(7403): p. 420-8.
- 1557 66. Shore, D.A., H. Yang, A.L. Balish, S.S. Shepard, P.J. Carney, J.C. Chang, C.T. Davis,
1558 R.O. Donis, J.M. Villanueva, A.I. Klimov, and J. Stevens, *Structural and antigenic*
1559 *variation among diverse clade 2 H5N1 viruses*. PLoS One, 2013. **8**(9): p. e75209.
- 1560 67. Sonnberg, S., R.J. Webby, and R.G. Webster, *Natural history of highly pathogenic*
1561 *avian influenza H5N1*. Virus Res, 2013. **178**(1): p. 63-77.
- 1562 68. Hidari, K.I., T. Murata, K. Yoshida, Y. Takahashi, Y.H. Minamijima, Y. Miwa, S.
1563 Adachi, M. Ogata, T. Usui, Y. Suzuki, and T. Suzuki, *Chemoenzymatic synthesis,*
1564 *characterization, and application of glycopolymers carrying lactosamine repeats as*
1565 *entry inhibitors against influenza virus infection*. Glycobiology, 2008. **18**(10): p. 779-
1566 88.
- 1567 69. Ogata, M., K.I. Hidari, W. Kozaki, T. Murata, J. Hiratake, E.Y. Park, T. Suzuki, and
1568 T. Usui, *Molecular design of spacer-N-linked sialoglycopolyptide as polymeric*
1569 *inhibitors against influenza virus infection*. Biomacromolecules, 2009. **10**(7): p. 1894-
1570 903.
- 1571 70. Shimizu, K., L. Wulandari, E.D. Poetranto, R.A. Setyoningrum, R. Yudhawati, A.
1572 Sholikhah, A.M. Natri, A.L. Poetranto, A.Y. Candra, E.F. Puruhito, Y. Takahara, Y.
1573 Yamagishi, M. Yamaoka, H. Hotta, T. Ustumi, M.I. Lusida, Soetjipto, Y.K. Shimizu,
1574 G. Soegiarto, and Y. Mori, *Seroevidence for a High Prevalence of Subclinical*
1575 *Infection With Avian Influenza A(H5N1) Virus Among Workers in a Live-Poultry*
1576 *Market in Indonesia*. J Infect Dis, 2016. **214**(12): p. 1929-1936.
- 1577 71. Le, M.Q., P. Horby, A. Fox, H.T. Nguyen, H.K. Le Nguyen, P.M. Hoang, K.C.
1578 Nguyen, M.D. de Jong, R.E. Jeeninga, H. Rogier van Doorn, J. Farrar, and H.F.

- 1579 Wertheim, *Subclinical avian influenza A(H5N1) virus infection in human, Vietnam.*
1580 *Emerg Infect Dis*, 2013. **19**(10): p. 1674-7.
- 1581 72. Robert, M., R. Holle du, V. Setiawaty, K.N. Pangesti, and E.R. Sedyaningsih,
1582 *Seroprevalence of avian influenza A/H5N1 among poultry farmers in rural Indonesia,*
1583 *2007. Southeast Asian J Trop Med Public Health*, 2010. **41**(5): p. 1095-103.
- 1584 73. Neumann, G., C.A. Macken, A.I. Karasin, R.A. Fouchier, and Y. Kawaoka, *Egyptian*
1585 *H5N1 influenza viruses-cause for concern?* *PLoS Pathog*, 2012. **8**(11): p. e1002932.
- 1586 74. Watanabe, Y., M.S. Ibrahim, and K. Ikuta, *Evolution and control of H5N1. A better*
1587 *understanding of the evolution and diversity of H5N1 flu virus and its host species in*
1588 *endemic areas could inform more efficient vaccination and control strategies.* *EMBO*
1589 *Rep*, 2013. **14**(2): p. 117-22.
- 1590 75. Arafa, A.S., S. Yamada, M. Imai, T. Watanabe, S. Yamayoshi, K. Iwatsuki-Horimoto,
1591 M. Kiso, Y. Sakai-Tagawa, M. Ito, T. Imamura, N. Nakajima, K. Takahashi, D. Zhao,
1592 K. Oishi, A. Yasuhara, C.A. Macken, G. Zhong, A.P. Hanson, S. Fan, J. Ping, M.
1593 Hatta, T.J. Lopes, Y. Suzuki, M. El-Husseiny, A. Selim, N. Hagag, M. Soliman, G.
1594 Neumann, H. Hasegawa, and Y. Kawaoka, *Risk assessment of recent Egyptian H5N1*
1595 *influenza viruses.* *Sci Rep*, 2016. **6**: p. 38388.
- 1596 76. Pflug, A., M. Lukarska, P. Resa-Infante, S. Reich, and S. Cusack, *Structural insights*
1597 *into RNA synthesis by the influenza virus transcription-replication machine.* *Virus*
1598 *Res*, 2017. **234**: p. 103-117.
- 1599 77. Boivin, S., S. Cusack, R.W. Ruigrok, and D.J. Hart, *Influenza A virus polymerase:*
1600 *structural insights into replication and host adaptation mechanisms.* *J Biol Chem*,
1601 2010. **285**(37): p. 28411-7.
- 1602 78. Einfeld, A.J., E. Kawakami, T. Watanabe, G. Neumann, and Y. Kawaoka, *RAB11A is*
1603 *essential for transport of the influenza virus genome to the plasma membrane.* *J Virol*,
1604 2011. **85**(13): p. 6117-26.
- 1605 79. Vignuzzi, M., J.K. Stone, J.J. Arnold, C.E. Cameron, and R. Andino, *Quasispecies*
1606 *diversity determines pathogenesis through cooperative interactions in a viral*
1607 *population.* *Nature*, 2006. **439**(7074): p. 344-8.
- 1608 80. Lauring, A.S. and R. Andino, *Quasispecies theory and the behavior of RNA viruses.*
1609 *PLoS Pathog*, 2010. **6**(7): p. e1001005.
- 1610 81. Banerjee, I., Y. Yamauchi, A. Helenius, and P. Horvath, *High-content analysis of*
1611 *sequential events during the early phase of influenza A virus infection.* *PLoS One*,
1612 2013. **8**(7): p. e68450.

- 1613 82. Killip, M.J., M. Smith, D. Jackson, and R.E. Randall, *Activation of the interferon*
1614 *induction cascade by influenza A viruses requires viral RNA synthesis and nuclear*
1615 *export*. J Virol, 2014. **88**(8): p. 3942-52.
- 1616 83. Amorim, M.-J., E.K. Read, R.M. Dalton, L. Medcalf, and P. Digard, *Nuclear Export*
1617 *of Influenza A Virus mRNAs Requires Ongoing RNA Polymerase II Activity*. Traffic,
1618 2007. **8**(1): p. 1-11.
- 1619 84. Read, E.K.C. and P. Digard, *Individual influenza A virus mRNAs show differential*
1620 *dependence on cellular NXF1/TAP for their nuclear export*. Journal of General
1621 Virology, 2010. **91**(5): p. 1290-1301.
- 1622 85. Iwai, A., T. Shiozaki, T. Kawai, S. Akira, Y. Kawaoka, A. Takada, H. Kida, and T.
1623 Miyazaki, *Influenza A virus polymerase inhibits type I interferon induction by binding*
1624 *to interferon beta promoter stimulator 1*. J Biol Chem, 2010. **285**(42): p. 32064-74.
- 1625 86. Graef, K.M., F.T. Vreede, Y.F. Lau, A.W. McCall, S.M. Carr, K. Subbarao, and E.
1626 Fodor, *The PB2 subunit of the influenza virus RNA polymerase affects virulence by*
1627 *interacting with the mitochondrial antiviral signaling protein and inhibiting*
1628 *expression of beta interferon*. J Virol, 2010. **84**(17): p. 8433-45.
- 1629 87. Carr, S.M., E. Carnero, A. Garcia-Sastre, G.G. Brownlee, and E. Fodor,
1630 *Characterization of a mitochondrial-targeting signal in the PB2 protein of influenza*
1631 *viruses*. Virology, 2006. **344**(2): p. 492-508.

1632